Protocol Number: D035940   ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL
_________________________________________________________________________________ 
Confidential Pag e 1 of 27 Prospect Ive, Randomized, SingLe-Blind, U.S. Mu Lti-Center Study to Eval Uate 
Treat Ment of Obstructive Sup Erficial Femoral Artery or Popliteal LesioN s With 
A Novel PacliT axel-Coat Ed Percutaneous Angioplasty Balloon  
ILLUMENATE Pivotal  Post-Approval Study  
PROTOCOL  
Pro
tocol Number:     D035940 
Revision Date:  14 April 2017 
Co-Nat
ional Principal Investigators : Prakash Krishnan, MD 
Klingenstein Clinical Center  
 
 
 
Sean Lyden, MD  
Cleveland Clinic Foundation 
 
 
Angiographic Core Laboratory: BIDMC  Angiographic Core Laboratory 
   
 
Duplex Ultrasound Core Laboratory: VasC ore 
 
 
Sponsor : Spectranetics Corporation  
9965 Federal Drive Colorado Springs, CO 80921 USA 

Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 2 of 27  
  
TABLE OF CONTENTS  
PROTOCOL SIGNATURE PAGE  ................................................................................................... 4 
SUMMARY OF CHANGES  .............................................................................................................. 4 
PROTOCOL S UMMARY  .................................................................................................................. 5 
1. Study Overview and Rationale  .................................................................................................. 7 
1.1 Background and Literature Review  ...................................................................................... 7 
2. DESCRIPTION OF THE STELLAREX 0.035 DEVICE AND CONTROL DEVICE  ........ 9 
2.1. Study Overview  ................................................................................................................. 9 
2.2. Stellarex ™ Device  .................................................................................................................. 10 
Basic Catheter Specifications  ...................................................................................................... 10 
Indications  ................................................................................................................................... 10 
2.3. Control Device  ....................................................................................................................... 10 
Basic Ca theter Specifications  ...................................................................................................... 10 
Indications  ................................................................................................................................... 10 
3. STUDY DESIGN ....................................................................................................................... 11 
3.1. Primary Endpoints  ................................................................................................................ 11 
Primar y Effectiveness Endpoint  .................................................................................................. 11 
Primary Safety Endpoint  ............................................................................................................. 11 
3.2. Secondary Endpoints  ............................................................................................................ 11 
3.3. Study Population  ................................................................................................................... 11 
3.4. Ethical Considerations  .......................................................................................................... 12 
3.5. Subject Discontinuation ........................................................................................................ 12 
3.6. Early Termination of the Clinical Trial  .............................................................................. 13 
4. CONDUCT OF THE STUDY .................................................................................................. 13 
4.1. Subject Medication Management  ........................................................................................ 13 
Subjects are required to be treated with ASA for the duration of the trial, (5 years) unless there 
is a contraindication to such.  Recommended ASA dose is 81 mg daily.  ................................... 13 
4.2. Subject Follow -up .................................................................................................................. 13 
5. ADVERSE EVENTS  ................................................................................................................. 14 
5.1. Adverse Events  ...................................................................................................................... 14 
5.2. Anticipated Adverse Events  ................................................................................................. 15 
5.3. Relationship to Study Device  ................................................................................................ 17 
5.4. Relationship to Study Procedure  ......................................................................................... 17 
5.5. Unanticipated Adverse Device Effect /Unanticipated Serious Adverse Device Effect  .... 17 
6. STATISTICAL DESIGN AND ANALYSIS  ........................................................................... 18 
6.1. Statistical Overview of the Trial  .......................................................................................... 18 
6.2 Analysis Populations  ............................................................................................................. 19 
6.3 Sample Size Justification  ...................................................................................................... 19 
6.4 Statistical Analyses  ................................................................................................................ 20 
General Statistical Considerations  ............................................................................................. 20 
Analyses of Primary Endpoint  ..................................................................................................... 20 
Analysis of Secondary Endpoints  ................................................................................................ 21 
Protection Against False Discovery  ............................................................................................ 21 
6.5 Blinding  .................................................................................................................................. 21 
7. RISK ASSESSMENT  ................................................................................................................ 21 
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 3 of 27  
 7.1. Poten tial Risks from Peripheral Catheterization, Stenting and PTA  .............................. 21 
7.2. Potential Risks from Paclitaxel Coating .............................................................................. 22 
7.3. Risk Management Procedure ............................................................................................... 22 
7.4. Potential Benefits  ................................................................................................................... 22 
8. DATA HANDLING, RECORD KEEPING AND REPORTING  ......................................... 22 
8.1. Case Report Form (CRF) Completion  ................................................................................ 22 
8.2. Source Documentation  .......................................................................................................... 23 
8.3. Reports  ................................................................................................................................... 23 
9. REGULATORY REQUIREMENTS  ...................................................................................... 23 
9.1. Investigator’s Responsibility  ................................................................................................ 23 
9.2. Compliance with Protocol and Protocol Amendments  ...................................................... 23 
9.3. Investigator Requirements  ................................................................................................... 24 
9.4. Institutional Requirements  ................................................................................................... 24 
9.5. Subject Informed Consent  .................................................................................................... 24 
9.6. Use of Information and Publication  ..................................................................................... 25 
9.7. Reporting Requirements  ....................................................................................................... 25 
10. SPONSOR RESPONSIBILITIES COMPLIANCE/QUALITY ASSURANCE .............. 26 
10.1.  Role of Sponsor  ...................................................................................................................... 26 
General Duties  ............................................................................................................................ 26 
Training of Investigator and Site Personnel and Monitoring ..................................................... 26 
Documentation  ............................................................................................................................ 26 
10.2.  Committees  ............................................................................................................................. 26 
Clinical Events Committee  .......................................................................................................... 26 
Data Safety Monitoring Board .................................................................................................... 27 
11. TRIAL TERMINATION ...................................................................................................... 27 
12. APPENDICES  ....................................................................................................................... 27 
 
• Appendix A:  Bibliographical References  
• Appendix B:  Helsinki Declaration   
• Appendix C :  Trial Abbreviations and Definitions  
• Appendix D :  Rutherford -Becker Classification Guidelines  
• Appendix E :  ABI Guidelines  
• Appendix F :  Walking Impairment Questionnaire Guidelines  
• Appendix G :  6 Minute Walking Test Instructions  
• Appendix H :  EQ -5D Instructions  
• Appendix I:  Investigator Responsibilities  
  
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 4 of 27  
 PROTOCOL SIGNATURE PAGE  
 
ILLUMENATE Pivotal  Post -Approval Study :    
Prospect Ive, Randomized, SingLe-Blind, U.S. Mu Lti-Center Study to Eval Uate 
Treat Ment of Obstructive Sup Erficial Femoral Artery or Popliteal LesioN s With 
A Novel PacliT axel-Coat Ed Percutaneous Angioplasty Balloon  
 
 
I have reviewed this protocol and agree to adhere to the requirements and responsibilities listed 
herein.  I am trained to the contents of this protocol, percutaneous angioplasty procedures, and the 
specific use of the devices listed in this protocol.  I w ill ensure that the study is conducted in 
compliance with the protocol, Instructions for Use, Good Clinical Practices, Declaration of Helsinki 
and all applicable regulatory requirements.  
 
 _______________________________   _____________________ 
Site Inves tigator Signature      Date  
   _______________________________  
Site Investigator Printed Name  
  
SUMMARY OF CHANGES  
Revision 
Level  Change 
Order  Description of Changes  
A   Initial Release  
 
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 5 of 27  
  PROTOCOL SUMMARY  
Device  Stellarex™ 0.035” Over -the-Wire (OTW) Drug -Coated Balloon (DCB)  (Stellarex DCB)  
Control  Bare Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter ( bare balloon 
catheter )) 
Study Objective  To continue  evaluate the long -term safety and effectiveness  of the Stellarex DCB  
Study Design  Continued follow -up of premarket ILLUMENATE Pivotal Study subjects  
Number of 
Subjects  300 subjects from the ILLUMENATE Pivotal study.  
200 DCB subjects  
100 PTA subjects    
Number of Sites  43 
Primary 
Effectiveness  
Endpoint  Patency at 24 months post -procedure.  Patency is defined as the absence of target lesion 
restenosis  as determined by duplex ultrasound (Peak Systolic Velocity Ratio (PSVR) ≤ 
2.5) and freedom from clinically -driven target lesion revascularization.  
Primary Safety 
Endpoint  Freedom from device and procedure -related death through 30 days post -procedure and 
freedom from target limb major amputation and  clinically -driven target lesion 
revascularization through 24 months post -procedure.  
Secondary 
Endpoints  • Major a dverse e vent (MAE) rate at 24, 36, 48 and 60 months post -procedure, defined 
as a composite rate of cardiovascular death, target  limb major amputation and 
clinically -driven target lesion revascularization (TLR).  
• Rate of clinically -driven target lesion reva scularization at 24 , 36, 48 and 60  months. 
• Rate of target lesion revascularization at 24 , 36, 48 and 60 months. 
• Rate of clinically -driven target vessel revascularization at 24 and 36, 48 and 60 
months. 
• Rate of target limb major amputation at 24, 36, 48 and 60 months. 
• Mortality rate at 24 , 36, 48 and 60 months. 
• Rate of occurrence of arterial thrombosis of the treated segment at 24, 36, 48 and 60 
months. 
• Patency rate at 24 and 36 months, defined as the absence of target lesion restenosis as determined  by duplex ultrasound (PSVR ≤ 2.5) and freedom from clinically -driven 
TLR  
• Change in a nkle-brachial i ndex (ABI) from pre -procedure to  24 and 36 months. 
• Change in walking impairment questionnaire (WIQ) from pre -procedure  to 24 and 36 
months.   
• Change in walk ing distance from pre -procedure to 24 and 36 months. 
• Change in Rutherford- Becker classification  from pre -procedure  to 24 and 36 months. 
• Change in EQ -5D from pre -procedure to 24 and 36 months. 
Follow -Up 
Schedule  • Office visits will occur at 24 and 36 months post -procedure to  review medication 
compliance, clinical assessments, functional status, adverse events and patency by 
duplex ultrasound.  
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 6 of 27  
 • Telephone contact will occur at 48 and 60 months post -procedure to review 
medication compliance and adverse events. Office visits are optional for these 
assessments.  
Planned  
Schedule  • Last subject last contact: 2020 
  
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 7 of 27  
 1. STUDY OVERVIEW AND RATIONALE  
1.1 Background and Literature Review  
Peripheral arterial disease (PAD) , atherosclerosis in vessels outside of the heart and brain,  is a 
common ailment affecting an estimated 27 million adults in Europe and North America and is 
associated with significant morbidity and mortality.1  Peripheral arterial disease is associated with 
significant reduction in health -related quality of life, and in extreme cases, the disease can result in 
debilitating symptoms ( including  loss of limbs).  Total disease prevalence has been estimated at 
between  3% and 10%, increasing to 15% to  20% in patients over 70 years.2  Only approximately  
25 percent of patients undergo treatment for the disease.3  Deterioration or progression of PAD 
occurs in one -third to one -fourth of all patients.4  One to five percent will eventually require 
amputation.4-6  
Peripheral arterial disease is associ ated with substantial morbidity and reduced health status 
measures.   The most common symptom of PAD is difficulty walking (intermittent claudication); 
less common is critical limb ischemia (CLI) which includes severe persistent rest pain requiring 
treatmen t with analgesics, ulceration or gangrene on the distal extremity.  Lower extremity arterial 
disease can lead to reduced mobility, limb pain, gangrene, and amputation, as well as increased mortality.
2,7,8  Physical function, pain, and general health perception is similar or worse than in 
patients with congestive heart failure  or recent myocardial infarction.  In addition, patients with 
PAD generally also present with cardiovascular disease (CVD) , which  may explain the increased 
risk of mortality from myocardial infarction (MI) and stroke,7,9,10 with mortality rates at five years 
ranging from 30% to 44%.11,12  
The superficial femoral artery (SFA) is the most commonly diseased artery in the peripheral (lower limb) vasculature, with PAD presenting as intermittent claudication.  Patients with intermittent claudicat ion report increased pain and limitations in physical functioning compared with published 
norms, which are expected based on the nature of their disease.   They also report significant 
deficits in energy, emotional reactions, sleep, and normal activit ies of daily living due to emotional 
stress.   These limitations have been reported to occur at a relatively low level of exercise.
4-6  
Available therapies for patients with PAD include: risk factor modification, including diabetes 
control, smoking cessation, and hyperlipidemia control; exe rcise therapy; pharmacological 
therapy; and surgical or endovascular revascularization.  Risk factor modification therapy is 
recommended to improve claudication and decrease the morbidity and mortality associated with 
the progression of PAD.2,13  Exercise therapy can produce clinical improvements in walking ability 
and reductions in claudication pain.2,13-15   Pharmacological options include antiplatelet and 
anticoagulant therapies.16-18  Surgery is typically reserved for patients with critical limb ischemia 
and is associated with risks such as wound complications, death, MI, infection and leg edema.18,19  
Patency rates at 1 year for surgical revascularization of the lower extremities have been reported to be 40- 80%.
20-22 
Multiple published studies report on the short and long -term results of performing percutaneous 
angioplasty interventions (including PTA without a drug coating) and/or stenting for PAD.  
Patency rates at 1 year have been reported to range between 29 -93%.23-42  A meta -analysis of PTA 
to treat SFA lesions up to 15 cm in length reported a 12- month primary patency rate of only 33%.43  
Treatment with bare metal self -expanding stents yields higher but variable 1- year patency  rates 
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 8 of 27  
 that range between 52%44 and 81%.45   
Restenosis remains a major limitation of  the clinical usefulness of PTA and stenting.  Poor long -
term results, especially after the treatment of longer lesions in the femoropopliteal region, have 
been reported.46-52  Paclitaxel is an antineoplastic drug that has demonstrated sustained inhibition 
of smooth muscle cell proliferation in several pre -clinical studies.53-56  Publications related to 
effectiveness of local administration of paclitaxel on restenosis through use of drug -coated 
balloons in the femoropopliteal artery have highlighted promising results with reduction of 
neointimal proliferation in the peripheral arteries.57-60 
Cassese et al. conducted a systematic meta- analysis of 4 randomized trials comparing paclitaxel 
drug- coated balloon (DCB) angioplasty to uncoated balloon (PTA) angioplasty.61 The primary 
endpoint was target lesion revascularization, with angiographic binary restenosis, late lumen loss, 
and all -cause mortality as secondary endpoints. The studies in the meta -analysis included 
THUNDER,57 FemPac,58 PACIFIER,62 and the LEVANT I study.60 The meta- analysis included 
381 patients with a median follow -up time of 10.3 months. The rate of TLRs was significantly 
lower in the patients treated with DCB (12.2%) in comparison to PTA (27.7%), with an odds ratio 
of 0.23 (95% confidence interval: 0.13 – 0.40, p< 0.00001). The authors concluded that DCB 
therapy has superior antirestenotic efficacy with no evidence of a differential safety profile.  
The IN.PACT SFA trial , a multi- center, randomized study  comparing the IN.PACT Admiral DCB 
(n=220) to the uncoated control balloon (n=111) in patients with femoropopliteal PAD , showed 
significantly higher primary patency for the DCB group (82.2%) vs. control (52.4%; P<0.001) at 12 months and at 24 months (78.9%  vs. 50.1%; P<0.001).
59,63  Clinically -driven TLR rates at 12 
months were 2.4% for the DCB group vs. 20.6% for control (P<0.001) and at 24 months were 
9.1% vs. 28.3% (P<0.001), respectively.59,63  A recent presentation at Vascular Interventional 
Advances (VIVA) in 2016 showed that the benefits of DCB over PTA wer e maintained out to 3 years with 
primary patency of 69.5% vs. 45.1% and CD TLR  rates of 15.2% vs. 31.1% for the DCB vs. PTA group.64 
The Lutonix DCB was also evaluated in a multi -center, randomized trial in comparison to an 
uncoated control PTA balloon, with 316 DCB subjects and 160 PTA subjects .  The results at 12 
months showed significantly better primary patency for the DCB group (65.2%) in comparison to the PTA group (52.6%; p=0.02), with similar  rates of target lesion revascularizations (12.3% DCB 
vs. 16.8% PTA).
65  
The Stellarex DCB has been studied in several clinical studies.  The initial experience included a 
prospective, multi -center, single arm clinical study performed in Europe, referred to as the 
ILLUMENATE First -in-Human (FIH) study.  The objective of the stu dy was to evaluate the safety 
and inhibition of restenosis of the Stellarex DCB for treatment of de novo or restenotic superficial 
femoral artery (SFA) or popliteal arteries. The first fifty (50) subjects were treated with pre -
dilatation prior to treatment with the Stellarex DCB (Cohort 1) and the second thirty (30) subjects 
were treated without the pre- dilatation step (Cohort 2). 
The results f rom Cohort 1 (with pre -dilatation)  showed that  the primary endpoint of LLL at 6 
months  (mean LLL 0.54±0.97mm; 95% c onfidence interval: 0.28 to 0.81mm) , as assessed by the 
angiographic core laboratory, was significantly less than the objective performance criterion 
(1.1mm).66 The major adverse event (MAE) rate at 6 months, defined as a composite rate of 
cardiovascular death, index limb amputation, and CD TLR , was 4.0% (95% confidence interval: 
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 9 of 27  
 0.5 to 13.7%), which was significantly lower than the pre -specified objective perfor manc e criterion 
(30%).66 The study  endpoints were met. The primary patency rate, defined as PSVR ≤ 2.5 without 
a CD TLR, was 89.5% at 12 months and 80.3% at 24 months (based on the Kaplan- Meier 
analysis). The freedom from CD TLR Kaplan -Meier rate was 90.0% at 12 months and 85.8% a t 24 
months.66 Additional ly, there were no amputations or cardiovascular deaths reported through 24 
months. 
The 2 -year results from Cohort 2 (Direct Cohort) were presented at Vascular Interventional 
Advances (VIVA) in 2015.67 Twenty -eight subjects with 37 lesions were included in the Cohort 2 
analysis; 2 su bjects were excluded because they were pre- dilated. The mean lesion length was 
6.4cm and calcification was present in 48.6% of lesions. At 6 months, the mean LLL was 0.03mm. 
The MAE rate was 14.8% at 12 months and 18.5% at 24 months, primarily driven by CD  TLRs. 
There was 1 index limb amputation observed within 6 months in conjunction with lower limb vessel thrombosis in a subject who had a stent placed during the procedure. The primary patency rate (per Kaplan -Meier analysis) was 86.2% at 12 months and 78.2% at 24 months, similar to the 
rates observed in the pre -dilatation cohort (Cohort 1). The freedom from CD TLR Kaplan -Meier 
rate was 85.4% at 12 months and 81.7% at 24 months.
67 
The 12- month results from the 2 randomized, controlled trials  studying the Stellarex DCB in 
comparison t o PTA control devices  have also been presented at scientific meetings.  Primary 
patency at 12 months was 83.9% vs. 60.6% in the ILLUMENATE EU RCT study (p<0.001) and 
76.3% vs. 57.6% in the ILLUMENATE Pivotal study (p=0.003).68,69  The CD TLR rates were also 
favourable for the Stellarex DCB in both studies (5.9% vs. 16.7% in the ILLUMENATE EU RCT 
study and 7.9% vs. 16.8% in the ILLUMENATE Pivotal study).68,69  The primary safety endpoint, 
defined as a composite of freedom from device and procedure -related death through 30 days and 
freedom from target limb major amputation and CD TLR  through 12 months, was also superior for 
the Stellarex DCB in comparison to PT A in both studies (94.1% vs. 83.3% through 395 days in the 
ILLUMENATE EU RCT study and 92.1% vs. 83.2% through 410 days in the ILLUMENATE 
Pivotal study [p=0.001]).68,69 
Numerous other drug-coated catheter systems using similar technology to that used in the 
ILLUMENATE Pivotal Study are currently commercially available. The Bard Lutonix drug -coated 
balloons and the Medtroni c IN.PACT Admiral paclitaxel- coated balloons are commercially 
available through CE Mark approval and Food and Drug Administration approval. Other CE Marked drug -coated balloons include, but may not be limited to, the Freeway balloon (Eurocor 
GmbH, Bonn, Ge rmany), the Passeo -18 Lux balloon (Biotronik), the Legflow OTW paclitaxel -
coated balloon (Cardionovum GmbH), Advance 18 PTX (Cook Medical), Luminor35 (iVascular), and the Elutax SV (Aachen Resonance GmbH).  
2. DESCRIPTION OF THE STELLAREX  0.035 DEVICE AND CONT ROL DEVICE  
2.1. Study Overview  
The ILLUMENATE Pivotal  PAS  is a continued follow -up study  which will include  300 subjects 
from  forty -three (4 3) sites across the United States and Austria  previously enrolled in the 
ILLUMENATE Pivotal pre -market study  to evaluate the Stellarex  DCB  compared to the PTA 
control device  for the treatment of de -novo or post -PTA occluded/stenotic or reoccluded/restenotic 
(except for in -stent) SFA and/or popliteal arteries.  
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 10 of 27  
 2.2. Stellarex ™ Device  
The Stellarex  DCB  is a commercially available PTA balloon catheter (EverCross ™ 0.035” PTA 
Balloon Catheter, Medtronic , Plymouth, MN 55441, USA)  coated with paclitaxel using a 
proprietary carrier.   
Basic Catheter Specifications  
•  Guidewire: 0.035”            
•  Balloon Length: 40/80/120 mm   
•  Sheath Compatibility: greater than or equal to 6 French  
•  Balloon Diameter: 4/5/6 mm  
•  Shaft length: 135 cm  
The nominal dose density of paclitaxel on the Stellarex  DCB  is 2.0 µ g/mm2.  The  nominal  dose 
of paclitaxel on a specific Stellarex  DCB  is listed  in Table 1.   
Table 1:   Nominal Paclitaxel Dose (µg) per Catheter Length/Diameter  
Balloon Diameter 
(mm)  Balloon Length (mm)  
40 80 120 
4 1124 µg  2211 µg  3307 µg  
5 1335 µg  2636 µg  3880 µg  
6 1619  µg 3174  µg 4721  µg 
 
Indications  
The Stellarex 0.035” OTW Drug- coated Angioplasty Balloon is indicated for percutaneous 
transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic 
lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference 
vessel diamet ers of 4 -6 mm.  
 
2.3. Control Device  
The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic , Plymouth, MN 55441, USA) .   
Basic Catheter Speci fications  
•  Guidewire: 0.035”            
•  Balloon Length: 40/80/120 mm   
•  Sheath Compatibility: greater to or equal to 6 French 
•  Balloon Diameter: 4/5/6 mm  
•  Shaft length: 135 cm  
Indications  
The EverCross  Balloon Catheter is intended to dilate stenosis in the iliac, femoral, ilio -femoral, 
popliteal, infra -popliteal, and renal arteries, and to treat obstructive lesions of native or 
synthetic arteriovenous dialysis fistulae.  This device is also indicated fo r stent post -dilation in 
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 11 of 27  
 the peripheral vasculature.   For additional information refer to the  EverCross  Instructions for 
Use. 
 
3. STUDY DESIGN  
The objective of this continued follow -up of ILLUMENATE Pivotal Study subjects is  to 
demonstrate the long term safety and eff ectiveness  of the Stellarex  DCB . 
Each  enrolled  subject will be followed for 5 years (60 months) after treatment.  A follow -up office 
visit will occur at 24 and 36 months.  A follow -up telephone contact or an optional office visit will 
occur at 48 and 60 months.   
3.1. Primary Endpoints  
Primary Eff ectiveness  Endpoint  
The primary eff ectiveness  endpoint for this study is patency at 24 months post -procedure.  Patency is 
defined as the absence of target lesion restenosis  as determined by duplex ultrasound ( Peak Systolic 
Velocity Ratio (PSVR) ≤  2.5) and freedom from  clinically -driven target lesion revascularization.  
Primary Safety Endpoint  
The primary safety endpoint for this study is freedom from device and procedure -related death 
through 30 days  post -procedure and  freedom from  target limb major amputation and clinically -
driven target lesion revascularization through 24 months post -procedure.  
3.2. Secondary Endpoints  
The following endpoints will be also evaluated as secondary endpoints:  
• Major a dverse e vent (MAE) rate at 24, 36, 48 and 60 months post -procedure, defined as a 
composite rate of cardiovascular death, target  limb major amputation and clinically -driven target 
lesion revascularization (TLR).  
• Rate of clinically -driven target lesion revasculariz ation at 24, 36, 48 and 60  months. 
• Rate of clinically -driven target vessel revascularization at 24 and 36, 48 and 60 months. 
• Rate of target limb major amputation at 24, 36, 48 and 60 months. 
• Mortality rate at 24 , 36, 48 and 60 months. 
• Rate of occurrence of  arterial thrombosis of the treated segment at 24, 36, 48 and 60 months . 
• Patency rate at 24 and 36 months, defined as the absence of target lesion restenosis  as 
determined  by duple x ultrasound (PSVR ≤ 2.5)  and freedom from clinically -driven TLR  
• Change in a nkle-brachial i ndex (ABI) from pre -procedure to  24 and 36 months. 
• Change in walking impairment questionnaire (WIQ) from pre -procedure  to 24 and 36 months.   
• Change in walking distance from pre -procedure to 24 and 36 months. 
• Change in Rutherford- Becker clas sification  from pre -procedure  to 24 and 36 months. 
• Change in EQ -5D from pre -procedure to 24 and 36 months. 
3.3. Study Population  
Subjects included in this study will be comprised of subjects enrolled in the ILLUMENATE Pivotal 
pre-market study .  Three hundred subjects  with documented symptomatic superficial femoral and/or 
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 12 of 27  
 popliteal artery disease who were eligible to be treated by interventional therapy and met all of the 
inclusion criteria and none of the exclusion criteria of th e Pivotal  study  were enrolled .  
3.4. Ethical Considerations  
The trial will be conducted in accordance with the ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with the International Conference on Harmonization Good Clinical Practices (ICH GCP), 21 Code of Federal Regulations (CFR) Parts 50, 54, 56, 812 and 814, International Organization for Standardization (ISO) 14155 [European Union (EU) only], and other applicable regulatory requirements.  
3.5. Subject Discontinuation 
Every subject should remain in the  trial until completion of the required follow -up period; however, 
a subject’s participation in any clinical trial is voluntary and the subject has the right to withdraw at any time without penalty or loss of benefit.  Whenever possible, the investigator should obtain written documentation from the subject that wishes to withdraw their consent for future follow -up 
visits and contact.  The reason for withdrawal, when it occurs, must be documented in the subject’s medical records.  Prior to study discontinuation, it is recommended that a final visit occur to assess clinical status, adverse ev ents and current medications .  The subject will be followed per the 
institution’s standard of care.  R easons for discontinuation may i nclude, but are not limited to, the 
following:  
• The investigator terminate s the subject’s participation if discontinuation in the study is  
deemed  medically necessary.  
• The subject does not complete the scheduled follow -up but has not ‘officially’ withdrawn 
from the trial (e.g. “lost to follow -up”).  This does not apply to missed visits.   
• The subject develops m edical conditions such as the following:  
o Reaction to acute treatment requires alternative treatment or intervention (e.g. allergic reaction to paclitax el, complication with non- study device) where study objectives 
cannot be objectively evaluated. 
o Unanticipated hospitalization requiring treatment or therapy conflictive with study objectives and preventing compliance with study requirements.  
Site personne l should make all reasonable efforts to locate and communicate with subjects at each 
contact time point.  A minimum of two telephone calls to contact the subject should be recorded in the source documents, including date, time, and initials of site personnel trying to make contact.  If these attempts are unsuccessful, a letter should be sent to the subject.  If the subject misses two consecutive scheduled contact time points and the above mentioned attempts at communicating with the subject are attempted bu t unsuccessful, the subject will be considered “lost to follow -up”.  
A study exit form must be completed when a)  the subject successfully completes the study, b) the 
subject is considered “lost to follow -up” (per the above criteria), c)  the subject withdraws f rom the 
study d)  the investigator withdraws the subject from the study  or e) the subject dies .  In each case of 
subject discontinuation, the Sponsor  must be notified of the reason for subject discontinuation.  The 
site will provide this information on the case report form (CRF) and in the source documents.  Withdrawn subjects will not be replaced in this trial.  
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 13 of 27  
 3.6. Early Termination of the Clinical Trial  
Spectranetics , the trial S ponsor, reserves the right to discontinue the clinical study at any stage, with 
suitable written notice to the investigator.  The investigator may also discontinue participation in the 
clinical trial with suitable written notice to the Sponsor .  
 Notification of suspension or termination will occur no later than five (5) business  days after the 
sponsor makes the determination.  In the event of study suspension or termination, the s ponsor will 
send a report outlining the circumstances to the IRB s/ECs  and all investigators.  A suspended or 
terminated study may not be re -initiated without approval of the reviewing  IRB/EC (where 
applicable).  The investigator should follow subjects as standard of care at the institution.  
 
4. CONDUCT OF THE STUDY 
4.1. Subject Med ication Management  
Subjects are required to be treated with ASA for the duration of the trial , (5 years) unless there is a 
contraindication to such.  Recommended ASA dose is 81 mg daily . 
The medication history will be updated as needed to include modifications to the anticoagulants, 
anti-platelets and statins following the procedure.  
4.2. Subject Follow -up  
Subjects will be followed at pre -determined time points during the study  as summarized in the 
Schedule of Events in Table 2 . 
 
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 14 of 27  
 Table 2:   Schedule of Events: 24 Months through 60 Months  
EVENT  24 Months  36 Months  48  Months  60 Months  Unscheduled*  Re-
intervention * 
Visit Window  730 ± 45 days 1095 ± 45 
days 1460 ± 45 
days 1825 ± 45 
days As clinically 
indicated  As clinically 
indicated  
Visit Type  Office  Office  Phone  Phone  Office  Office  
Anticoagulant s, 
Antiplatelet s, and 
Statins        
Peripheral Angiogram 
with Runoff        
Duplex Ultrasound 
Examination        
Ankle -Brachial Ind ex       
Rutherford -Becker 
Classification        
6-Minute Walking Test        
WIQ        
EQ-5D       
Health Economic 
Evaluation        
Adverse Events        
* NOTE: While an attempt should be made to collect all non -invasive testing at unscheduled visits or re -
interventions , a protocol deviation will not be required if all assessments are not completed. For re -interventions, 
the angiogram and duplex ultrasound should be completed per the respective core laboratory guidelines.  
 
 
5. ADVERSE EVENTS  
5.1. Adverse Events  
At each evaluation, the investigator will determine whether any adverse events (AEs) have occurred.  For the purpose s of this protocol, an adverse  event  is any untoward medical occurrence  in a study 
subject which occurs or worsens , whether or not considered related to the study device , study 
procedures, or study requirements . 
Serious adverse event s (SAEs)  are any untoward medical occurrence that results in death, is life-
threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, requires medical/surgical intervention to prevent life -
threatening illness or injury or to prevent permanent impairment of a body structure or function, or is a congenital anomaly/birth defect.   Emergency room visits lasting less than 24 hours are not 
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 15 of 27  
 considered SAEs.   
Major adverse events (MAE s) include cardiovascular death, t arget  limb  major  amputation and 
clinically -driven target lesion revascularizations. Refer to Appendix C for definitions. 
Subjects should be encouraged to report AEs spontaneously or in response to general, non -directed 
questioning.  Additionally, subjects should be instructed to contact the investigator if any SAEs 
occur between study visits.  If it is determined that an AE h as occurred, the investigator should 
obtain all the information required to complete the AE CRF. The sponsor may request AE source documentation from  the site to facilitate adjudication of AEs.   
Adverse event reporting began  when the subject was enrolled i n the ILLUMENATE Pivotal study .  
All S AEs and MAEs  are to be captured and reported to the sponsor via the AE CRF within 10 
business days  of the investigator lear ning of the event  in the US, and within 3 business days in the 
EU.  The site should not wait for full details to make the initial report to the sponsor .  The site is 
responsible for reporting AEs to the IRB/EC according to the board’s  reporting guidelines.  
For each AE  the following should be documented on the appropriate CRF : start date of the event, 
treatment, resolution, assessment of seriousness, relationship to the study device and relationship to the study procedure.  Adverse events should be followed to resolution or stabilization.  
Adverse events that are present at the end of a subject’s participation in the study should be marked as on -going on the CRF  and the subject should receive post -treatment follow -up as appropriate and 
standard of care at the institution.   All adverse events from enrollment in the ILLUMENATE Pivotal 
study through c ompletion of this post -approval study will be reported.  
5.2. Anticipated Adverse Events  
An anticipated adverse event is any untoward medical occurrence in a subject whether or not 
considered related to the investigational product(s) or drug regimen prescribed a s part of the 
protocol, predefined in the protocol and/or Instruction for Use that is identified or worsens during a clinical study.  
The following is a list of adverse events that may result from the PTA procedure.  
 
• Abnormal heart rhythms during the 
procedure  • Hemorrhage  
• Abrupt closure  • Hypertension  
• Allergic reaction to contrast, concomitant 
medications  • Hypotension  
• Amputation  • Injury to the groin blood vessel  
• Aneurysm  • Infection or pain at insertion site  
• Arrhythmias (bradycardia & tachycardia)  • Inflammation  
• Arterial dissection  • Ischemia  
• Arterial perforation or rupture  • Leucopenia  
• Artery spasm  • Lymphocele  
• Arteriovenous ( AV) fistula  • Myocardial Infarction  
• Bleeding  • Nausea  
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 16 of 27  
 • Bypass graft surgery (emergent or non-
emergent)  • Pseudoaneurysm  
• Chest pain  • Renal failure  
• Coagulopathy  • Respiratory failure  
• Congestive heart failure  • Restenosis  
• Death (cardiovascular or non-
cardiovascular related)  • Sepsis  
• Discomfort during the procedure  • Seizure  
• Distal emboli  • Shock  
• Embolism/PTA catheter embolism  • Stroke/ cerebrovascular accident ( CVA )  
• Endocarditis  • Wound complication or wound infection  
• Femoral nerve compression with 
associated neuropathy  • Thrombocytopenia  
• Fever  • Thrombosis  
• Groin area bruising  • Total occlusion  
• Hematoma  • Unstable/stable angina  
 
The following is a list of theoretical adverse events that may result from the addition of paclitaxel 
to a PTA catheter:  
 
• Abdominal pain  • Leucopenia  
• Abnormal liver function test  • Male hypogonadism  
• Acne  • Myalgia  
• Allergic reaction to paclitaxel  • Pain  
• Alopecia  • Peripheral neuropathy  
• Anemia  • Pneumonia  
• Coagulopathy  • Pyelonephritis  
• Edema (non -pulmonary)  • Rash  
• Gastrointestinal issues (e.g.  diarrhea, 
vomiting, nausea, pain)  • Renal tubular necrosis  
• Hematologic dyscrasia (including 
neutropenia)  • Sepsis  
• Hemolysis  • Thrombocytopenia  
• Hypercholesterolemia  • Transfusion  
• Hyperlipidemia  • Urinary tract infection  
• Hypertension  • Viral, bacterial and fungal infections  
• Hypertriglyceridemia   
 
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 17 of 27  
 5.3. Relationship to Study Device  
The investigator will use the following definitions to assess the relationship of the adverse event to 
the use of study device:  
Not Related  
 The event is definitely not associated with device application. The 
adverse event is due to an underlying or concurrent illness or effec t of 
another device or drug.  
Unlikely  
 An adverse event has little or no temporal relationship to the study device and/or a more likely alternative etiology exists.  
Possible  
 
 The temporal sequence between device application and the event is 
such that the relationship is not unlikely or subject’s condition or concomitant therapy could have caused the AE.  
Probable  
 The temporal sequence is relevant or the event abates upon device application completion/removal or the event cannot be reasonably explained  by the subject’s condition. 
Highly 
Probable  
 The temporal sequence is relevant and the event abates upon device application completion/removal, or reappearance of the event on repeat device application. 
5.4. Relationship to Study Procedure  
The investigator will use the following definitions to assess the relationship of the adverse event to the original ILLUMENATE Pivotal study procedure:  
 
Not Related  
 The event is definitely not associated with the study procedure.  The 
adverse event is due  to an underlying or concurrent illness or effect of 
another device or drug.  
Unlikely  
 An adverse event has little or no temporal relationship to the study 
procedure and/or a more likely alternative etiology exists.  
Possible  
 
 The temporal sequence between the study procedure and the event is such that the relationship is not unlikely or subject’s condition or concomitant therapy could have caused the AE.  
Probable  
 The temporal sequence is relevant or the event abates upon study procedure completion or the event cannot be reasonably explained by the subject’s condition. 
Highly 
Probable  
 The temporal sequence is relevant and the event abates upon study 
procedure completion, or reappearance of the event on repeat 
interventional procedures (re -challeng e). 
 
5.5. Unanticipated Adverse Device Effect /Unanticipated Serious Adverse Device Effect  
An unanticipated adverse device effect (UADE) is defined as any serious adverse effect on health or safety or any life- threatening problem or death caused by, or associated with, a device, if that effect, 
problem, or death was not previously identified in nature, severity, or degree of incidence in the 
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 18 of 27  
 investigational plan or protocol, or any other unanticipated serious problem associated with a device 
that relates to the rights, safety or welfare of subjects.    
An unanticipated serious adverse device effect is defined as any serious adverse device effect which by its nature, incidence, severity or outcome has not been identified in the current version of the risk analysis report.  Anticipated serious adverse device effect (ASADE) is an effect which by its nature,  
incidence, severity or outcome has been identified in the risk analysis report. 
If a complication occurs that the investigator believes may be a potential UADE /USADE , the s ite 
should immediately contact the s ponsor.  All UADEs /USADEs  must be documented by the 
investigator including the date of onset, a complete description of the event, possible reason(s) for 
the event, duration, actions taken and outcome  and submitted to the sponsor  as soon as possible .  
Reporting of UADEs in the US by the investigator must be no more than 10 business  days after the 
investigator learns of the effect .  Reporting of USADEs in the EU by the investigator must be  within 
3 business days.  Copies of all supporting documents should be submitted concurrently w ith the 
appropriate CRF.   
The investigator will submit to the reviewing IRB a report of any UADE that occurs as soon as 
possible, but no more than 10 business  days after the investigator learns of the effect , or sooner if 
required by the board’s reporting  guidelines.  USADEs should be reported as soon as possible after 
the event or being informed about the event to the EC. 
A report from the s ponsor will be submitted to the Food and Drug Administration ( FDA ) and to all 
reviewing IRB /ECs and participating in vestigators within 10 business  days after the s ponsor first 
receives notice of the effect.   
All UADEs will be followed until resolution, stabilization or 30 days after the last patient enrolled 
has completed the trial, whichever occurs first.  
Risk A ssessment  
In conjunction with the National Principal Investigator (s) and/or, if need be, the Clinical Event 
Committee  and/or Data Safety Monitoring  Board  (Section 10.2) the s ponsor shall decide 
whether, as a result of an UADE /USADE , the safety of study participants is at risk, or whether 
continuation of the trial is in jeopardy.   
Corrective M easures  
If any situation potentially jeopardizing the safe ty of subjects, users or third persons arise 
during a clinical trial or approved performance evaluation, then the s ponsor and those persons 
carrying out the clinical trial or the performance evaluation shall immediately take all of the essential safety measures in order to protect subjects, users or third persons from direct or indirect danger.  
 
6. STATISTICAL DESIGN AND ANALYSIS  
6.1. Statistical Overview of the Trial  
The statistical design of this study is that of a single -blind randomized controlled trial in which there 
are two co -primary endpoints.  The endpoints and their corresponding statistical hypotheses are:  
• Non-inferior Safety: Freedom from device and procedure related death through 30 days 
post-procedure and freedom from target limb major amputation  and clinically -driven 
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 19 of 27  
 target lesion revascularization through 24 months post -procedure.  
o H0: πDCB ≤ πPTA - δ 
o H1: πDCB > πPTA - δ where π is the population proportion for the 
corresponding treatment group and δ is the non- inferiority margin.  
• Superior Effectiveness: Patency at 24 months post -procedure, defined as the absence of 
target lesion restenosis determined by duplex ultrasound PSVR ≤ 2.5 and freedom from 
target lesion revascularization.    
o H0: πDCB ≤ πPTA 
o H1: πDCB > πPTA 
The analysis populations are Intention- to-Treat (ITT) and Per -Protocol (PP); they are fully 
defined below in the next subsection. 
6.2 Analysis Populations  
The Intention- to-Treat  (ITT)  population will be comprised of all subjects who successfully 
complete d the preliminary qualification procedures and were subsequently randomized to receive 
either the Stellarex DCB  or the PTA control device.  
The P er-Protocol (PP)  population will consist of ITT subjects who had no bail -out stenting and no 
major protocol devi ations .  The data for each subject will be reviewed by the blinded angiographic 
core laboratory . All trial endpoints will be analyzed using both the Intention- to-Treat and Per -
Protocol populations , with the ITT analysis a priori  designated as primary . 
6.3 Sample Size Justification  
Statistical sample size estimation for the two co -primary endpoints are as follows:   
Effectiveness:   
• Superiority design  
• 2:1 treatment assignment ratio  
• 80% power  
• 1-tailed alpha = 0.025  
• Patency proportions: PTA =  47% , representing a reduction of approximately 10% in  the 
PTA group from 12 months , and a  diffe rence between groups of 19 % (approximately  the 
observed difference between groups in patency at 12 months)  
• Therefore N = 2 36 subjects (= 1 57 + 79 ) 
Safety:   
• Non-inferiority design  
• 2:1 randomization ratio 
• 80% power  
• 1-tailed 0.025 
• Non-inferiority margin = 10%  
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 20 of 27  
 • Success proportions:  PTA  success rate = 73 %, representing a reduction of 10% in the 
PTA group from month 12, and a difference between groups in favor of DC B of 7%  (as 
compared to an observed difference of 8.9%  at month 12)  
• Therefore N’ = 206 subjects (=1 37 + 69 ) 
The enrolled sample size of 300 will be sufficient to achieve 80% power for the primary efficacy and 
safety objectives . It is expected that no more than 20% of subjects will not be evaluable for the 
primary endpoints (due to early withdrawals, missing data or non- diagnostic/non- evaluable DUS 
assessment)  providing an expected observed sample size of 240. However, all subjects will be 
included in the analysis as multiple imputation , and clinical imputation for patency, will be 
employed for subjects with missing endpoint data . 
The non- inferiority margin has been increased from 5% for the 12 month endpoint in the P ivotal 
study to 10% for the PAS endpoint at 24 months. The reason for the increase to the more conventional 10% margin is because an assumption of a 20% difference , the original assumption for 
the 12 month endpoint, between groups at 24 months is not reasonable given the 12 month results of 92.1%  vs. 83.2% . 
6.4 Statistical Analyses  
General Statistical Considerations  
Continuous data will be summarized using descriptive statistics:  n, mean, standard deviation, median, minimum and maximum.  Continuous variables that are recorded using approximate values  (e.g., < or >) will be replaced by the closest exact value for the calculation of summary 
statistics.  Categorical variables will be summarized using frequency counts and percentages. For ordinal -scaled variables, a combination of the above may be employe d as appropriate:  
frequency and percentage of observations within a category and means and standard deviations of the scores of the categories.  For categorical and ordinal variables, percentages will be calculated based on non -missing data.  
A statistical analysis plan (SAP)  accompanies this protocol and should be referred to for 
further information on intended statistical methods; the SAP  will be finalized and approved 
prior to study database lock.  The SAP will detail the analytical methodology and assum ptions 
beyond those presented below. 
Analyses of Primary Endpoint  
Both co- primary endpoints are binary in nature and as such will be summarized as success (or 
failure) counts, percentages, and Clopper -Pearson 95% confidence intervals.  Superiority in 
effec tiveness will be tested  using chi -square contingency table methods, corrected for 
continuity.  In the unlikely event that Cochran’s Rule is violated, then Fisher’s Exact tests will be employed. The primary analysis of the primary endpoint s will employ multiple imputation 
on the ITT cohort to replace missing values.  Details of the imputation model are provided in the SAP.  
Non-inferiority of safety event rates will employ Farrington -Manning non- inferiority exact 
tests.   Secondary analyses of the primary endpoints , including Kaplan -Meier methods  and 
sensitivity analyses such as use of all TLR in endpoints defined with clinically -driven TLR will 
be performed and are detailed in the SAP.  
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 21 of 27  
 Analysis of Secondary Endpoints  
All secondary endpoints will be analyze d descriptively without hypothesis -testing . 
For binary variables such as MAE or technical success, counts, percentages and exact 95% 
confidence intervals using Clopper -Pearson’s method will be calculated.  For continuous 
variables, means, standard deviations and 95% confidence intervals will be calculated.   
Protection Against False Discovery  
Insofar as this study is not deemed a success unless both co- primary endpoints (safety and 
effectiveness) are met, the probability that the trial falsely succeeds purely due to chance is related to the product of the individual endpoint α -levels.  Since the endpoints are effectively 
independent, the probability that both endpoints are met purely by chance is less than 1 out of 1000. 
6.5 Blinding  
Blinding is critical to the integrity of this clinical trial.  Blinding of the treating physician is not possible due to the differences between the investigational and control devices.  For the duration of 
the trial the subject and the c ore laboratories will be blinded.     
In the event of a medical emergency, UADE, or pregnancy in an individual subject, in which knowledge of the investigational product is critical to the subject’s health management, the treating physician may act in accordance with knowledge of the actual randomized treatment assignment of the subject.   
The need to act on knowledge of the treatment assignment must first be discussed with the sponsor .  
Should the trial be suspended or pre -maturely terminated, the s ponsor will provide instructions 
regarding th e release of the randomized treatment assignment.  
 
7. RISK ASSESSMENT  
7.1. Potential Risks from Peripheral Catheterization, Stenting and PTA  
It is expected that risks associated with this study to be not significantly different than those with the 
standard interventional procedure for SFA disease.  The list of adverse events that may result from 
peripheral intervention includes but is not limit ed to: abrupt closure, acute myocardial infarction, 
allergic reaction to contrast, amputation, aneurysm, arterial perforation, arterial rupture, arteriovenous fistula, atrial arrhythmias (including bradycardia and tachycardia), bleeding complications that may require transfusions, artery spasm, stent embolism, peripheral artery or catheter thrombosis or embolism, chest pain, coagulopathy, congestive heart failure, death, drug reactions to antiplatelet agents/contrast medium, discomfort, emergency or non- emergent bypass 
graft surgery, distal emboli (air, tissue or thrombotic), fever, hypotension, hypertension, infection and pain at insertion site, injury to the peripheral artery, ischemia, leucopenia, lymphocele, nausea and vomiting, ps eudoaneurysm, restenosi s of the treated segment of the artery, sepsis, seizure, 
stroke/cerebrovascular accident (CVA), thrombocytopenia, total occlusion of the peripheral artery, unstable or stable angina pectoris, vascular complications including entry site that may require vessel repair, ventricular arrhythmias including ventricular fibrillation, ventricular tachycardia, 
wound complication or wound infection, renal failure, urinary tract infection and arterial dissection.  
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 22 of 27  
 7.2. Potential Risks from Paclitaxel Coating 
Local vessel to xicity from the paclitaxel coating includes the possibility of thrombosis and aneurysm 
formation.  Certain side effects and discomforts have been reported in subjects that have received 
paclitaxel in intravenous (IV) form as part of chemotherapy treatment.   These subjects may have 
other comorbid conditions and/or have received concomitant medications that may also have contributed to the reported side effects.  In the IV setting, the dose is delivered throughout the body and in doses hundreds of times highe r than the total amount present on the CVI Paclitaxel -coated 
PTA Catheter  used in this clinical study.  The side effects reported by the chemotherapy subjects 
include allergic/immunologic reactions, alopecia, anemia, blood product transfusion, gastro-intestinal symptoms, hematologic dyscrasia (including leukopenia, neutropenia, and thrombocytopenia), hepatic enzyme changes, histologic changes in vessel wall, cellular damage or necrosis, myalgia/arthralgia and peripheral neuropathy.  It is unlikely with the total dosage on the CVI Paclitaxel -coated PTA Catheter  and the targeted v essel delivery of the paclitaxel that the side 
effects associated with IV high dose chemotherapy would occur.  
7.3. Risk Management Procedure  
The study will be conducted by skilled and trained investigators relative to interventional procedures.  The research te am at each clinical site will undergo training prior to initiation of the 
study.  
Subjects will be monitored closely throughout the study duration.  Subjects will be evaluated at pre -
determined time points to assess their clinical condition.  The subject’s  medication regimen will be 
in line with standard of care requirements for peripheral interventional procedures.  
7.4. Potential Benefits  
The local application of anti -proliferative drugs (e.g., sirolimus, zotarolimus, everolimus, and 
paclitaxel) for prevention  of restenosis in coronary arteries via a stent delivery system has shown 
that these therapies successfully inhibit or reduce restenosis.
70-81 This has reduced the need for 
subjects with coronary artery disease to undergo repeat percutaneous and surgical revascularizations. 
The success of drug -eluting stents in the coronary arteries triggered an increased interest in using 
drug- eluting or drug -coated therapies in other vascul atures.  Neointimal hyperplasia remains one of 
the major stumbling blocks of all endoluminal therapies, particularly in the small caliber peripheral 
vessels and long diseased segments.50,52 To date , most trials involving drug -coated or drug -eluting 
stents have not shown reduced restenosis rates in the superficial femoral or proximal popliteal 
arteries.   
Preliminary data suggest that drug -coated balloons using paclitaxel reduce restenosis and late lu men 
loss in the superficial femoral and proximal popliteal arteries when compared to PTA with standard balloon catheters.
57,58 Therefore, drug -coated balloons may have more advantages than angioplasty 
alone, especially in terms of controlling neointimal hyperplasia and lowering restenosis rates.   
 
8. DATA HANDLING, RECORD KEEPING AND REPORTING  
8.1. Case Report Form (CRF) Completion  
All required data will be accurately recorded by authorized personnel on standard CRFs which will 
be provided by the Sponsor . CRFs should be completed within 10 business days of a completed 
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 23 of 27  
 study visit.  
8.2. Source Documentation  
Source documentation is defined as all information necessary for the reconstruction and evaluation 
of the clinical investigation.  Regulations require that investigators maintain information in the subject’s medical records, which corroborate data collected on the CRFs.  Investigators will maintain all records pertaining to this study as mandated by the hospital requirements and national laws and regulations (e.g. informed consent evidence; nurse notes; hospital charts; correspondence with the sponsor, regulatory authorities or other physicians).  
8.3. Reports  
A report will be created after the primary endpoint has been analyzed and a final report on the study will be completed at the end of the study.  Interim reports may be compiled per regulatory requirements . 
 
9. REGULATORY REQUIREMENTS  
This study will be conducted in compliance with the protocol approved by  study sites’ respective 
Institutional Review Board s (IRB) /Ethics Committees (ECs)  and according to the Declaration of 
Helsinki, International Conference on H armonization Good Clinical Practice (ICH GCP), Title 21 of 
the Code of Federal Regulations (CFR) Parts 50, 54, 56, 812, and 814, and other applicable 
regulatory requirements.  No planned deviations from the protocol will be implemented without prior review  and approval of the  sponsor then submitted to IRB/EC pursuant to IRB /EC guidelines. 
In such cases, the deviation will be reported to the IRB /EC as soon as possible.  
9.1. Investigator’s Responsibility  
The investigator must read and understand the protocol and must sign and complete an investigator 
agreement form.  The investigator agreement form documents the investigator’s agreement to all conditions of the protocol and an agreement to conduct the study  accordingly.   
Additional requirements must be met by the investigator and participating institution, such as compliance with the protocol and protocol amendments, investigator requirements, institutional requirements, subject informed consent, use of inf ormation and publication, and reporting 
requirements.  
9.2. Compliance with Protocol and Protocol Amendments  
A protocol deviation is defined as  any divergence from the study protocol .  The investigator is 
responsible for promptly reporting protocol deviations t o their IRB /EC per IRB /EC policy and to the 
sponsor.  The s ponsor will determine the effect of the protocol deviation on the scientific soundness 
of the clinical study and subject safety and determine if additional reports or actions are required.  Additio nal action may include site re -training , removal of the devices , and/or site termination.   
The investigator will not implement any changes to the protocol without first obtaining a written agreement from the s ponsor and documented approval from the IRB /EC, except in the event of an 
immediate hazard to the subject.  The investigator will report the deviation in accordance with the applicable regulations.   
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 24 of 27  
 9.3. Investigator Requirements  
All investigators were approved by the sponsor as part of the ILLUMENATE Pivotal study  and 
remain in good standing  with the following required documentation  
•  Signed investigator’s agreement  
• Current curriculum vitae  
• Financial disclosure form  
• IRB/EC approval of the investigator  
Investigators must allow  the Sponsor  or representati ves of the Sponsor  to visit the site to periodically 
assess the data quality and study integrity.  On site, the Sponsor  or representatives will review study 
records in comparison with source documents, discuss the conduct of the study and verify that the 
facilities remain acceptable.  In addition the study may be evaluated by government inspectors who 
must be allowed access to CRFs, source documents and other study files.   
The investigator must notify the Sponsor  promptly of any inspections scheduled by re gulatory 
authorities, and promptly forward copies of inspection reports to Sponsor . 
The investigator should retain essential documents at least two years after the last approval of a 
marketing application and until there are no pending or contemplated mark eting applications, or at 
least two years have elapsed since the formal discontinuation of clinical development of the investigational product.  These documents should be retained for a longer period, however if required by the applicable regulatory requir ements or by an agreement with the s ponsor. The 
investigator must contact the sponsor prior to disposal of study records. 
If the investigator withdraws from the study, the responsibility for follow -up and maintaining the 
study records must be transferred t o a responsible party (such as another study investigator).  Notice 
of transfer must be provided in writing by the investigator to the sponsor, FDA /CA and IRB /EC no 
later than 10 business days after the transfer occurs. 
9.4. Institutional Requirements  
The inves tigator and institution are required to submit the following documentation.. 
•  IRB/EC approved informed consent form  
•  IRB/EC approval of the protocol  
• Fully executed clinical study agreement  
Any additional requirements imposed by the IRB /EC or regulatory authorities concerning the trial 
shall be followed.  The investigation may not start at the institution until favorable IRB and/or 
regulatory approval has been obtained.  
9.5. Subject Informed Consent  
Study subjects were required to provide written informed consent  using an IRB -/EC-approved 
informed consent form  as part of the ILLUMENATE Pivotal study .  No additional follow -up 
requirements or testing is required as part of this post -approval study.   
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 25 of 27  
 9.6. Use of Information and Publication  
All inf ormation and data generated in association with this study will be held in strict confidence 
until the study completion.  The investigator agrees to use this information for the sole purpose of 
completing this study and for no other purpose without written consent from  the sponsor. 
At the conclusion of each follow -up time point and the entire study, an abstract reporting the primary 
results may be prepared and presented in an appropriate international forum.  A manuscript may also be prepared for publication in a scientific journal. The data and results from the study are the sole property of  the sponsor .  The sponsor  shall have the right to access and use all data and results 
generated during the study.  The sponsor  acknowledges that the Principal Investiga tor(s) might 
desire to publish a multi -center publication regarding the trial results.  The sponsor  must receive any 
proposed publication and/or presentation materials at least 60 days prior to the proposed date of the presentation or the initial submissio n of the proposed publication in order for the materials to be 
reviewed by  the sponsor  in compliance with the  sponsor’s  publication policy set forth in the clinical 
study agreement  or investigator a greement.  
9.7. Reporting Requirements  
Report ing requirements fo r the investigator are listed in Table 4.  Included are information regarding 
to whom this information is to be sent, and the frequency and time constraints around submissions.  If applicable laws, regulations, or IRB /EC requirements mandate stricter reporting requirements than 
those listed, the stricter requirements must be followed.  
Table 2:   Site Responsibilities for Submitting Data and Reports  
Type of Report   Investigator Reporting Responsibili ties 
Report 
Prepared For  Reporting Time Frame  
Adverse Events  Sponsor  Adverse events are collected a t the time of the 
procedure and follow -up visits  and must be reported 
to the sponsor as soon as possible.  
Serious Adverse Events  Sponsor and 
IRB/EC/CA  For US: ASAP, but to sponsor within 10 business 
days of the investigator learning of the event.  To 
IRB according to board guidelines.  
For EU : ASAP, but to sponsor within 3 business 
days of the investigator learning of the event. To 
IRB/EC according to board guidelines.  
Submission to CA is done by the sponsor as soon as  
possible.  
Unanticipated Adverse Device 
Effects  Sponsor and 
IRB/EC ASAP, but to sponsor within 10 business days of the 
investigator learning of the effect.  To IRB /EC 
according to board guidelines.  
Withdrawal of IRB /EC Approval or 
other action on part of the IRB /EC 
that affects the study  Sponsor  Within 5 business  days of IRB /EC decision.  
Progress Reports  (US Only)  Sponsor and 
IRB/EC Every 6 months for the first two y ears and then a t 
intervals dictated by the IRB /EC, but no less than 
yearly.  
Protocol Deviations  Sponsor and 
IRB/EC ASAP  to sponsor .  To IRB /EC according to board 
guidelines.  
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 26 of 27  
 Type of Report   Investigator Reporting Responsibili ties 
Report 
Prepared For  Reporting Time Frame  
Final Report  Sponsor and 
IRB/EC For US: To sponsor within 3 months after 
termination or completion of study or investigator’s 
participation.   
For EU: To sponsor within 6 months after termination or completion of study or investigator’s 
participation.   
To IRB /EC according to board guidelines.  
Other  IRB/EC/CA , 
FDA  Upon request to  provide accurate, complete, and 
current information about any aspect of the study.  
 
10. SPONSOR RESPONSIBILITIES COMPLIANCE/QUALITY ASSURANCE  
10.1. Role of Sponsor  
As the study s ponsor, Spectranetics  has the overall responsibility for the conduct of the study, 
including assurance that the study satisfies regulatory requirements . 
General Duties  
It is the s ponsor’s responsibility to ensure that the study is conducted according to the ethical 
principles that have their origin in the Declaration of Helsinki and consistent with ICH GCP, 
21 CFR Parts 50, 54, 56 and 812, International Organization for Standardization (ISO) 14155 
[European Union (EU) only]  and other applicable regulatory  requirements , the study protocol, 
or any conditions of approval imposed by the IRB /CA/EC  or regulatory authorities.  
Additionally, the s ponsor will ensure proper clinical site monitoring is conducted.   
Training of Investigator and Site Personnel and Moni toring 
The training of the investigator, and appropriate clinical site personnel will be the responsibility of the s ponsor and Principal Investigator, or designee, and may be conducted 
during an investigator meeting, a site initiation visit, or other appro priate training sessions.  
Periodic monitoring visits will be conducted frequently enough to ensure that all clinical subject data are properly documented and that the study is properly conducted.  
Documentation  
The s ponsor will collect, store, guard and e nsure completion by the relevant parties of the 
following documents:  
• Records of any UADEs reported to the s ponsor during the clinical investigation 
• Any statistical analyses and underlying supporting data  
• The final report of the clinical investigation  
10.2. Committees  
Clinical Events Committee  
The Clinical Events Committee (CEC) is made up of interventional radiologists, interventional cardiologists or vascular surgeons who are not participants in the study.  The CEC  is charged 
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  PROTOCOL  
_________________________________________________________________________________ 
Confidential   Page 27 of 27  
 with the development of specifi c criteria used for the categorization of clinical events and 
clinical endpoints in the study which are based on the protocol.  
At the onset of the trial, the CEC will establish explicit rules outlining the minimum amount of 
data required, and the algorithm followed in order to classify a clinical event. All members of the CEC will be blinded to the primary results of the trial during the period of primary endpoint data collection . 
The CEC will meet regularly to review and adjudicate all clinical events. Th e committee will 
review and rule on all deaths that occur throughout the trial.  The committee will also review and rule on patency when there are two modalities of images available (ultrasound and angiographic) and they are in conflict with each other.   
Data  Safety  Monitoring Board 
The Data Safety Monitoring Board  (DSM B) will consist of at least 5 members with 3 members 
representing a quorum.  Membership will include a biostatistician and independent 
representatives in relevant fields of clinical expertise, including but not limited to , physicians 
with one of the following specialties: interventional cardiology, vascular surgery, or  
interventional radiology.  DSM B members will be not part of the study or committees related 
to the study.  The DSM B will advise the sponsor regarding the continuing safety of trial 
subjects, including those to be recruited, as well as the continuing validity and scientific merit of the trial.  
 
11. TRIAL TERMINATION 
The s ponsor and Steering Committee  will monitor the progress ion of the study.  If warranted, the 
study may be suspended or discontinued early if there is an observation of serious adverse reactions presenting an unreasonable risk to the study population.   
Notification of suspension or termination will occur no lat er than five (5) business  days after sponsor 
makes the determination.  In the event of study suspension or termination, the s ponsor will send a 
report outlining the circumstances to the IRB s/ECs  and all investigators.  A suspended or terminated 
study may not be reinitiated without approval of the reviewing  IRB/EC (where applicable).  The 
investigator should follow any subjects as standard of care at the institution.   The s ponsor has the right to terminate the trial at any time for any reason.  
 
12. APPENDICES  
• Appendix A:   Bibliographical References  
• Appendix B:  Helsinki Declaration   
• Appendix C :   Trial Abbreviations and Definitions  
• Appendix D :  Rutherford -Becker Classification Guidelines  
• Appendix E : ABI Guidelines  
• Appendix F : WIQ Guidelines  
• Appendix G : 6 Minute Walking Test Instructions  
• Appendix H : EQ-5D Instructions  
• Appendix I:  Investigator Responsibilities  
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  APPENDIX A:  Bibliographical References  
_________________________________________________________________________________ 
____________________________________________________________________________ 
Confidential                                                                                                             Page 1 of 6  
  
Appendix A:  Bibliographical References  
1. Belch JJ, Topol EJ, Agnelli G, et al. Critical issues in peripheral arterial disease detection and 
management: a call to action. Arch Intern Med. 2003;163(8):884- 892. 
2. Norgren L, Hiatt WR, Dormandy JA, et al. Inter -Society Consensus for the Management of  
Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45 Suppl S:S5- 67. 
3. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180-189. 
4. Murphy TP. Medical outcomes studies in peripheral vascular disease. J Vasc Interv Radiol. 
1998;9(6):879- 889. 
5. Pentecost MJ, Criqui MH, Dorros G, et al. Guidelines for peripheral percutaneous transluminal angioplasty of the abdominal aorta and lower extremity vessels. A statement for health professionals from a special writing group of the Councils on Cardiovascular Radiology, Arteriosclerosis, Cardio- Thoracic and Vascular Surgery, Clinical Cardiology, and 
Epidemiology and Prevention, the Americ an Heart Association. Circulation. 1994;89(1):511-
531. 
6. Weitz JI, Byrne J, Clagett GP, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation. 1996;94(11):3026- 3049. 
7. Dieter RS, Chu WW, Pacanowski JP, Jr., McBride PE, Tanke TE. The significance of lower 
extremity peripheral arterial disease. Clin Cardiol. 2002;25(1):3- 10. 
8. McDermott MM, Criqui MH, Greenland P, et al. Leg strength in peripheral arterial disease: 
associations with diseas e severity and lower -extremity performance. J Vasc Surg. 
2004;39(3):523- 530. 
9. Goshima KR, Mills JL, Sr., Hughes JD. A new look at outcomes after infrainguinal bypass surgery: traditional reporting standards systematically underestimate the expenditure of  effort 
required to attain limb salvage. J Vasc Surg. 2004;39(2):330- 335. 
10. Goessens BM, van der Graaf Y, Olijhoek JK, Visseren FL, Group SS. The course of vascular risk factors and the occurrence of vascular events in patients with symptomatic peripheral arterial disease. J Vasc Surg. 2007;45(1):47- 54. 
11. Lassila R, Lepantalo M, Lindfors O. Peripheral arterial disease --natural outcome. Acta Med 
Scand. 1986;220(4):295- 301. 
12. Vogt MT, Wolfson SK, Kuller LH. Lower extremity arterial disease and the aging  process: a 
review. J Clin Epidemiol. 1992;45(5):529- 542. 
13. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aorti c): a collaborative report from the American Association for Vascular 
Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the AC C/AHA Task Force on Practice Guidelines (Writing Committee to 
Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, an d Blood Institute; Society for Vascular Nursing; TransAtlantic Inter -
Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113(11):e463- 654. 
14. Hiatt WR, Wolfel EE, Meier RH, Regensteiner JG. Superiority of treadmill walking exercise versu s strength training for patients with peripheral arterial disease. Implications for the 
mechanism of the training response. Circulation. 1994;90(4):1866- 1874.  
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  APPENDIX A:  Bibliographical References  
_________________________________________________________________________________ 
____________________________________________________________________________ 
Confidential                                                                                                             Page  2 of 6  
 15. Brunelle CL, Mulgrew JA. Exercise for intermittent claudication. Physical therapy. 
2011;91(7) :997- 1002.  
16. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001;344(21):1608- 1621. 
17. Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).  CAPRIE Steering Committee. Lancet. 1996;348(9038):1329-
1339. 
18. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter -Society Consensus (TASC). J Vasc Surg. 2000;31(1 Pt 
2):S1 -S296. 
19. Tisi PV, Cowan AR, Morris GE. Endoluminal femoropopliteal bypass for intermittent claudication. Eur J Vasc Endovasc Surg. 2000;19(5):481- 488. 
20. Conte MS, Bandyk DF, Clowes AW, et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg. 2006;43(4):742- 751; discussion 751. 
21. Faries PL, Logerfo FW, Arora S, et al. A comparative study of alternative conduits for lower extremity revascularization: all- autoge nous conduit versus prosthetic grafts. J Vasc Surg. 
2000;32(6):1080- 1090.  
22. Abbott WM, Green RM, Matsumoto T, et al. Prosthetic above -knee femoropopliteal bypass 
grafting: results of a multicenter randomized prospective trial. Above -Knee Femoropopliteal 
Study Group. J Vasc Surg. 1997;25(1):19- 28. 
23. Minar E, Pokrajac B, Maca T, et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty : results of a prospective randomized study. Circulation. 2000;102(22):2694- 2699. 
24. Cejna M, Thurnher S, Illiasch H, et al. PTA versus Palmaz stent placement in 
femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol. 2001;12(1):23- 31. 
25. Grimm J, Muller -Hulsbeck S, Jahnke T, Hilbert C, Brossmann J, Heller M. Randomized 
study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions. J Vasc Interv Radiol. 2001;12(8):935- 942. 
26. Zdanowski Z, Albrechtsson U, Lundin A, et al. Percutaneous transluminal angioplas ty with 
or without stenting for femoropopliteal occlusions? A randomized controlled study. Int Angiol. 1999;18(4):251- 255. 
27. Whyman MR, Fowkes FG, Kerracher EM, et al. Is intermittent claudication improved by percutaneous transluminal angioplasty? A randomized controlled trial. J Vasc Surg. 1997;26(4):551- 557. 
28. Vroegindeweij D, Vos LD, Tielbeek AV, Buth J, vd Bosch HC. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: A comparative randomized study. Cardiovasc Intervent Radiol. 1997;20(6):420- 425. 
29. Stanley B, Teague B, Raptis S, Taylor DJ, Berce M. Efficacy of balloon angioplasty of the superficial femoral artery and popliteal artery in the relief of leg ischemia. J Vasc Surg. 
1996;23(4):679- 685. 
30. Murray JG, Apthorp LA, Wilkins RA. Long -segment (> or = 10 cm) femoropopliteal 
angioplasty: improved technical  success and long -term patency. Radiology. 1995;195(1):158-
162. 
31. Gordon IL, Conroy RM, Tobis JM, Kohl C, Wilson SE. Determinants of patency after 
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  APPENDIX A:  Bibliographical References  
_________________________________________________________________________________ 
____________________________________________________________________________ 
Confidential                                                                                                             Page  3 of 6  
 percutaneous angioplasty and atherectomy of occluded superficial femoral arteries. Am J 
Surg. 1994;168(2):115- 119. 
32. Matsi PJ, Manninen HI. Impact of different patency criteria on long -term results of 
femoropopliteal angioplasty: analysis of 106 consecutive patients with claudication. J Vasc Interv Radiol. 1995;6(2):159- 163. 
33. Hunink MG, Donaldson MC, Meyer ovitz MF, et al. Risks and benefits of femoropopliteal 
percutaneous balloon angioplasty. J Vasc Surg. 1993;17(1):183- 192; discussion 192- 184. 
34. Do dai D, Triller J, Walpoth BH, Stirnemann P, Mahler F. A comparison study of self -
expandable stents vs balloon angioplasty alone in femoropopliteal artery occlusions. Cardiovasc Intervent Radiol. 1992;15(5):306- 312. 
35. Johnston KW. Femoral and popliteal arteries: reanalysis of results of balloon angioplasty. Radiology. 1992;183(3):767- 771. 
36. Capek P, McLean G K, Berkowitz HD. Femoropopliteal angioplasty. Factors influencing 
long-term success. Circulation. 1991;83(2 Suppl):I70 -80. 
37. Jeans WD, Armstrong S, Cole SE, Horrocks M, Baird RN. Fate of patients undergoing transluminal angioplasty for lower -limb ischemia. Radiology. 1990;177(2):559- 564. 
38. Murray RR, Jr., Hewes RC, White RI, Jr., et al. Long -segment femoropopliteal stenoses: is 
angioplasty a boon or a bust? Radiology. 1987;162(2):473- 476. 
39. Hewes RC, White RI, Jr., Murray RR, et al. Long -term results of superficial femoral artery 
angioplasty. AJR Am J Roentgenol. 1986;146(5):1025- 1029. 
40. Krepel VM, van Andel GJ, van Erp WF, Breslau PJ. Percutaneous transluminal angioplasty of the femoropopliteal artery: initial and long -term results. Radiology. 1985; 156(2):325- 328. 
41. Gallino A, Mahler F, Probst P, Nachbur B. Percutaneous transluminal angioplasty of the arteries of the lower limbs: a 5 year follow -up. Circulation. 1984;70(4):619- 623. 
42. Muradin GS, Bosch JL, Stijnen T, Hunink MG. Balloon dilation and stent implantation for 
treatment of femoropopliteal arterial disease: meta -analysis. Radiology. 2001;221(1):137-
145. 
43. Rocha -Singh KJ, Jaff MR, Crabtree TR, Bloch DA, Ansel G, Viva Physicians I. Performance 
goals and endpoint assessments for clinical t rials of femoropopliteal bare nitinol stents in 
patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv. 2007;69(6):910- 919. 
44. Sabeti S, Schillinger M, Amighi J, et al. Primary patency of femoropopliteal arteries treated with ni tinol versus stainless steel self -expanding stents: propensity score -adjusted analysis. 
Radiology. 2004;232(2):516- 521. 
45. Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femora l artery and proximal popliteal artery: twelve -month 
results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 3(3):267 -276. 
46. Schillinger M, Sabeti S, Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared wit h balloon angioplasty with optional stenting. Circulation. 
2007;115(21):2745- 2749. 
47. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354(18):1879 -1888. 
48. Lugmayr HF, Holzer H, Kastner M, Riedelsberger H, Auterith A. Treatment of complex arteriosclerotic lesions with nitinol stents in the superficial femoral and popliteal arteries: a midterm follow -up. Radiology. 2002;222(1):37- 43. 
49. Becquemin JP, F avre JP, Marzelle J, Nemoz C, Corsin C, Leizorovicz A. Systematic versus 
selective stent placement after superficial femoral artery balloon angioplasty: a multicenter 
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  APPENDIX A:  Bibliographical References  
_________________________________________________________________________________ 
____________________________________________________________________________ 
Confidential                                                                                                             Page  4 of 6  
 prospective randomized study. J Vasc Surg. 2003;37(3):487- 494. 
50. Cheng SW, Ting AC, Lau H, Wong J. Immediate stenting of iliofemoral occlusive lesions: a 
surgeon's early experiences. J Endovasc Surg. 1999;6(3):256- 263. 
51. Gordon IL, Conroy RM, Arefi M, Tobis JM, Stemmer EA, Wilson SE. Three -year outcome 
of endovascular treatment of superfic ial femoral artery occlusion. Arch Surg. 
2001;136(2):221- 228. 
52. DeRubertis BG, Pierce M, Chaer RA, et al. Lesion severity and treatment complexity are associated with outcome after percutaneous infra- inguinal intervention. J Vasc Surg. 
2007;46(4):709- 716. 
53. Albrecht T, Speck U, Baier C, Wolf KJ, Bohm M, Scheller B. Reduction of stenosis due to intimal hyperplasia after stent supported angioplasty of peripheral arteries by local administration of paclitaxel in swine. Invest Radiol. 2007;42(8):579- 585. 
54. Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004;110(7):810- 814. 
55. Scheller B, Speck U, Schmitt A, Bohm M, Nickenig G. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol. 2003;42(8):1415- 1420.  
56. Speck U, Scheller B, Abramjuk C, et al. Neointima inhibition: c omparison of effectiveness of 
non-stent -based local drug delivery and a drug -eluting stent in porcine coronary arteries. 
Radiology. 2006;240(2):411- 418. 
57. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358(7):689- 699. 
58. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel -coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. 
Circulation. 2008;118(13):1358- 1365. 
59. Tepe G, Laird J, Schneider P, et al. Drug- coated balloon versus standard percutaneous 
transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12 -month results from the IN.PACT SF A randomized trial. Circulation. 
2015;131(5):495- 502. 
60. Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix paclitaxel -coated balloon for 
the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human ra ndomized trial of low -dose drug- coated balloon versus uncoated balloon 
angioplasty. JACC Cardiovascular interventions. 2014;7(1):10- 19. 
61. Cassese S, Byrne RA, Ott I, et al. Paclitaxel -coated versus uncoated balloon angioplasty 
reduces target lesion revas cularization in patients with femoropopliteal arterial disease: a 
meta -analysis of randomized trials. Circ Cardiovasc Interv. 2012;5(4):582- 589. 
62. Werk M, Albrecht T, Meyer DR, et al. Paclitaxel -coated balloons reduce restenosis after 
femoro -popliteal an gioplasty: evidence from the randomized PACIFIER trial. Circ 
Cardiovasc Interv. 2012;5(6):831- 840. 
63. Laird JR, Schneider PA, Tepe G, et al. Durability of Treatment Effect Using a Drug -Coated 
Balloon for Femoropopliteal Lesions: 24- Month Results of IN.PAC T SFA. Journal of the 
American College of Cardiology. 2015;66(21):2329- 2338. 
64. Krishnan P. Drug -Coated Balloons Show Superior Three -Year Outcomes vs. Angioplasty: 
Results from IN.PACT SFA Randomized Trials. Paper presented at: Vascular Interventaional Advances (VIVA)2016; Las Vegas, NV.  
65. Rosenfield K, Jaff MR, White CJ, et al. Trial of a Paclitaxel -Coated Balloon for 
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  APPENDIX A:  Bibliographical References  
_________________________________________________________________________________ 
____________________________________________________________________________ 
Confidential                                                                                                             Page  5 of 6  
 Femoropopliteal Artery Disease. N Engl J Med. 2015;373(2):145- 153. 
66. Schroeder H, Meyer DR, Lux B, Ruecker F, Martorana M, Duda S. Two- year results of a 
low-dose drug -coated balloon for revascularization of the femoropopliteal artery: Outcomes 
from the ILLUMENATE first -in-human study. Catheter Cardiovasc Interv. 2015. 
67. Krishnan P. Stellarex ILLUMENATE First- in-Human study: 24- month res ults of the direct -
DCB cohort. Paper presented at: VIVA2015; Las Vegas, NV.  
68. Lyden S. ILLUMENATE Pivotal Stellarex DCB IDE Study 12 -Month Result. Paper 
presented at: Transcatether Cardiovascular Therapeutics2016; Washington, D.C. 
69. Brodmann M. ILLUMEN ATE European Clinical Trial: 12 -Month Final Results for the 
Stellarex DCB. Paper presented at: The Amputation Prevention Symposium2016; Chicago, 
IL. 
70. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus -coated stents in human coronary arteries: a quantitative coronary angiography and 
three- dimensional intravascular ultrasound study. Circulation. 2001;103(2):192- 195. 
71. Moses JW, Leon MB, Popma JJ, et al. Sirolimus -eluting stents versus standard stents in  
patients with stenosis in a native coronary artery. N Engl J Med. 2003;349(14):1315- 1323. 
72. Stone GW, Ellis SG, Cox DA, et al. A polymer -based, paclitaxel -eluting stent in patients 
with coronary artery disease. N Engl J Med. 2004;350(3):221- 231. 
73. Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of the sirolimus -eluting 
stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004;43(6):1110- 1115. 
74. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer -based paclitaxel -eluting stent 
with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005;294(10):1215- 1223.  
75. Serruys PW, Ruygrok P, Neuzner J, et al. A randomised comparison of an everolimus -eluting 
coronary stent with a paclitaxel -eluting coronary stent:the SPIRIT II trial. EuroIntervention. 
2006;2(3):286- 294. 
76. Meredith IT, Ormiston J, Whitbourn R, et al. Fir st-in-human study of the Endeavor ABT -
578-eluting phosphorylcholine -encapsulated stent system in de novo native coronary artery 
lesions: Endeavor I Trial. EuroIntervention. 2005;1(2):157- 164. 
77. Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double -blind, multicenter study of the 
Endeavor zotarolimus -eluting phosphorylcholine -encapsulated stent for treatment of native 
coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006;114(8):798- 806. 
78. Kandzari DE, Leon MB, Popma JJ, et al. Comparison of zotarolimus -eluting and sirolimus -
eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. 2006;48(12):2440- 2447.  
79. Leon MB, Mauri L, Popma JJ, et al. A randomized comparison of the ENDEAVOR zotarolimus -eluting stent versus the TAXUS paclitaxel- eluting stent in de novo native 
coronary lesions 12- month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol. 
2010;55(6):543- 554. 
80. Stone GW, Midei M, Newman W, e t al. Randomized comparison of everolimus -eluting and 
paclitaxel -eluting stents: two -year clinical follow -up from the Clinical Evaluation of the 
Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Art ery Lesions (SPIRIT) III trial. Circulation. 2009;119(5):680- 686. 
81. Hermiller JB, Fergus T, Pierson W, et al. Clinical and angiographic comparison of everolimus -eluting and paclitaxel -eluting stents in small coronary arteries: a post hoc 
Protocol Number: D035940    ILLUMENATE Pivotal PAS  
Spectranetics  APPENDIX A:  Bibliographical References  
_________________________________________________________________________________ 
____________________________________________________________________________ 
Confidential                                                                                                             Page  6 of 6  
 analysis of the SPIRIT III randomized trial. Am Heart J. 2009;158(6):1005 -1010. 
 
Protocol Number: D035940   ILLUMENATE Pivotal  PAS Protocol  
Spectranetics Appendix B:  Helsinki Declaration  
______________________________________________________________________________ 
Confidential  Page 1 of 5 WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI  
Ethical Principles for Medical Research Involving Human Subjects  
• Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and 
amended by the:  
• 29th WMA General Assembly, Tokyo, Japan, October 1975  
• 35th WMA General Assembly, Venice, Italy, October 1983  
• 41st WMA General Assembly, Hong Kong, September 1989 
• 48th WMA General Assembly, Somerset West, Republic of South Africa, October 
1996 
• 52nd WMA General Assembly, Edinburgh, Scotland, October 2000 
• 53rd WMA General Assembly, Washington 2002 (Note of Clarification on paragraph 
29 added)  
• 55th WMA General Assembly, Tokyo 2004 (Note of Clarification on Paragraph 30 
added)  
• 59th WMA General Assembly, Seoul, October 2008 
 
A. INTRODUCTION  
1. The World Medical Association (WMA) has developed the Declaration of Helsinki as a 
statement of ethical principles for medical research involving human subjects, including 
research on identifiable human material and data. The Declaration is intended to be read 
as a whole and each of its constituent paragraphs should not be applied without consideration of all other relevant paragraphs.  
2. Although the Declaration is addressed primarily to physicians, the WMA  encourages 
other participants in medical research involving human subjects to adopt these principles.  
3. It is the duty of the physician to promote and safeguard the health of patients, including those who are involved in medical research. The physician's knowledge and conscience are dedicated to the fulfilment of this duty. 
4. The Declaration of Geneva of the WMA binds the physician with the words, “The health of my patient will be my first consideration,” and the International Code of Medical Ethics declares t hat, “A physician shall act in the patient's best interest when providing 
medical care.” 
5. Medical progress is based on research that ultimately must include studies involving human subjects. Populations that are underrepresented in medical research should be provided appropriate access to participation in research.  
6. In medical research involving human subjects, the well -being of the individual research 
subject must take precedence over all other interests.  
7. The primary purpose of medical research involving hum an subjects is to understand the 
causes, development and effects of diseases and improve preventive, diagnostic and 
Protocol Number: D035940   ILLUMENATE Pivotal  PAS Protocol  
Spectranetics Appendix B:  Helsinki Declaration  
______________________________________________________________________________ 
Confidential  Page 2 of 5 therapeutic interventions (methods, procedures and treatments). Even the best current 
interventions must be evaluated continually through re search for their safety, 
effectiveness, efficiency, accessibility and quality.  
8. In medical practice and in medical research, most interventions involve risks and burdens. 
9.  Medical research is subject to ethical standards that promote respect for all human 
subjects and protect their health and rights. Some research populations are particularly 
vulnerable and need special protection. These include those who cannot give or refuse 
consent for themselves and those who may be vulnerable to coercion or undue influe nce. 
10. Physicians should consider the ethical, legal and regulatory norms and standards for research involving human subjects in their own countries as well as applicable international norms and standards. No national or international ethical, legal or regul atory 
requirement should reduce or eliminate any of the protections for research subjects set 
forth in this Declaration.  
B. PRINCIPLES FOR ALL MEDICAL RESEARCH  
11. It is the duty of physicians who participate in medical research to protect the life, health, 
digni ty, integrity, right to self -determination, privacy, and confidentiality of personal 
information of research subjects.  
12. Medical research involving human subjects must conform to generally accepted scientific principles, be based on a thorough knowledge of t he scientific literature, other relevant 
sources of information, and adequate laboratory and, as appropriate, animal experimentation. The welfare of animals used for research must be respected.  
13. Appropriate caution must be exercised in the conduct of medica l research that may harm 
the environment.  
14. The design and performance of each research study involving human subjects must be clearly described in a research protocol. The protocol should contain a statement of the ethical considerations involved and should indicate how the principles in this Declaration have been addressed. The protocol should include information regarding funding, 
sponsors, institutional affiliations, other potential conflicts of interest, incentives for 
subjects and provisions for treatin g and/or compensating subjects who are  harmed as a 
consequence of participation in the research study. The protocol should describe 
arrangements for post -study access by study subjects to interventions identified as 
beneficial in the study or access to oth er appropriate care or benefits.  
15. The research protocol must be submitted for consideration, comment, guidance and approval to a research ethics committee before the study begins. This committee must  be 
independent of the researcher, the sponsor and any other undue influence. It must  take 
into consideration the laws and regulations of the country or countries in which the  
research is to be performed as well as applicable international norms and standards but  
these must not be allowed to reduce or eliminate a ny of the protections for research 
subjects set forth in this Declaration. The committee must have the right to monitor ongoing studies. The researcher must provide monitoring information to the committee, 
Protocol Number: D035940   ILLUMENATE Pivotal  PAS Protocol  
Spectranetics Appendix B:  Helsinki Declaration  
______________________________________________________________________________ 
Confidential  Page 3 of 5 especially information about any serious adverse e vents. No change to the protocol may 
be made without consideration and approval by the committee. 
16. Medical research involving human subjects must be conducted only by individuals with 
the appropriate scientific training and qualifications. Research on patie nts or healthy 
volunteers requires the supervision of a competent and appropriately qualified physician 
or other health care professional. The responsibility for the protection of research  subjects 
must always rest with the physician or other health care p rofessional and never  the 
research subjects, even though they have given consent.  
17. Medical research involving a disadvantaged or vulnerable population or community is  
only justified if the research is responsive to the health needs and priorities of this  
population or community and if there is a reasonable likelihood that this population or  
community stands to benefit from the results of the research.  
18. Every medical research study involving human subjects must be preceded by careful  
assessment of predictable risks and burdens to the individuals and communities  involved 
in the research in comparison with foreseeable benefits to them and to other  individuals or 
communities affected by the condition under investigation.  
19. Every clinical trial must be registered in a publicly accessible database before recruitment of the first subject.  
20. Physicians may not participate in a research study involving human subjects unless they are confident that the risks involved have been adequately assessed and can be  
satisfactorily managed. Physicians must immediately stop a study when the risks are  
found to outweigh the potential benefits or when there is conclusive proof of positive  and 
beneficial results.  
21. Medical research involving human subjects may only be conducted if the impor tance of  
the objective outweighs the inherent risks and burdens to the research subjects.  
22. Participation by competent individuals as subjects in medical research must be voluntary. 
Although it may be appropriate to consult family members or community leader s, no 
competent individual may be enrolled in a research study unless he or she  freely agrees.  
23. Every precaution must be taken to protect the priva cy of research subjects and the 
confidentiality of their personal information and to mini mize the impact of th e study on 
their physical, mental and social integrity.  
24. In medical research involving competent human subjects, each potential subject must be  
adequately informed of the aims, methods, sources of funding, any possible conflicts of  
interest, institutional a ffiliations of the researcher, the anticipated benefits and potential 
risks of the study and the discomfort it may entail, and any other relevant aspects of the  
study. The potential subject must be informed of the right to refuse to participate in the  
study or to withdraw consent to participate at any time without reprisal. Special attention 
should be given to the specific information needs of individual potential  subjects as well 
as to the methods used to deliver the information. After ensuring that  the po tential subject 
has understood the information, the physician or another  appropriately qualified 
Protocol Number: D035940   ILLUMENATE Pivotal  PAS Protocol  
Spectranetics Appendix B:  Helsinki Declaration  
______________________________________________________________________________ 
Confidential  Page 4 of 5 individual must then seek the potential subject’s freely -given informed consent, 
preferably in writing. If the consent cannot be expressed in writing, the non- written 
consent must be formally documented and witnessed.  
25. For medical research using identifiable human material or data, physicians must  normally 
seek consent for the collection, analysis, storage and/or reuse. There may be situations 
where consent would be impossible or impractical to obtain for such research or would pose a threat to the validity of the research. In such situations the research may  be done 
only after consideration and approval of a research ethics committee.  
26. When seeking informed consent for participation in a research study the physician should be particularly cautious if the potential subject is in a dependent relationship with the 
physician or may consent under duress. In such situations the informed consent  should be 
sought by an appropriately qualified individual who is completely independent of this 
relationship.  
27. For a potential research subject who is incompetent, the physician must seek informed 
consent from the legally authorized representative. These individuals must not be  
included in a research study that has no likelihood of benefit for them unless it is  intended 
to promote the health of the population represented by the potential subject, the research cannot instead be performed with competent persons, and the research  entail s only 
minimal risk and minimal burden.  
28. When a potential research subject who is deemed incompetent is able to give assent to  
decisions about participation in research, the physician must seek that assent in addition 
to the consent of the legally authorized representative. The potential subject’s dissent  
should be respected.  
29. Research involving subjects who are physically or mentally incapable of giving consent, for example, unconscious patients, may be done only if the physical or mental  condition 
that prevents giving informed consent is a necessary characteristic of the research 
population. In such circumstances the physician should seek informed consent  from the 
legally authorized representative. If no such representative is available and if  the r esearch 
cannot be delayed, the study may proceed without informed consent  provided that the 
specific reasons for involving subjects with a condition that renders  them unable to give 
informed consent have been stated in the research protocol and the study has been 
approved by a research ethics committee. Consent to remain in the  research should be 
obtained as soon as possible from the subject or a legally authorized representative.  
30. Authors, editors and publishers all have ethical obligations with regard to t he publication 
of the results of research. Authors have a duty to make publicly available  the results of 
their research on human subjects and are accountable for the completeness and accuracy 
of their reports. They should adhere to accepted guidelines for ethical  reporting. Negative 
and inconclusive as well as positive results should be published or  otherwise made 
publicly available. Sources of funding, institutional affiliations and conflicts of interest should be declared in the publication. Reports of re search not in  accordance with the 
principles of this Declaration should not be accepted for  publication.  
 
Protocol Number: D035940   ILLUMENATE Pivotal  PAS Protocol  
Spectranetics Appendix B:  Helsinki Declaration  
______________________________________________________________________________ 
Confidential  Page 5 of 5 C. ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH  
MEDICAL CARE  
31. The physician may combine medical research with medical care only to the extent that  the 
research is justified by its potential preventive, diagnostic or therapeutic value and if  the 
physician has good reason to believe that participation in the research study will not  
adversely affect the health of the patients who serve as research subjects.  
32. The benefits, risks, burdens and effectiveness of a new intervention must be tested  against 
those of the best current proven intervention, except in the following circumstances:  
• The use of placebo, or no treatment, is acceptable in studies where no current  proven 
intervention exists; or  
• Where for compelling and scientifically sound me thodological reasons the use of 
placebo is necessary to determine the efficacy or safety of an intervention and the 
patients who receive placebo or no treatment will not be subject to any risk of serious 
or irreversible harm. Extreme care must be taken to avoid abuse of this option.  
33. At the conclusion of the study, patients entered into the study are entitled to be  informed 
about the outcome of the study and to share any benefits that result from it, for example, 
access to interventions identified as beneficial in the study or to other  appropriate care or 
benefits.  
34. The physician must fully inform the patient which aspects of the care are related to the 
research. The refu sal of a patient to participate in a study or the patient’s decision to 
withdraw from the study must never interfere with the patient- physician relationship.  
35. In the treatment of a patient, where proven interventions do not exist or have been ineffective, t he physician, after seeking expert advice, with informed consent from the  
patient or a legally authorized representative, may use an unproven intervention if in the  
physician's judgment  it offers hope of saving life, re -establishing health or alleviating  
suffering. Where possible, this intervention should be made the object of research, 
designed to evaluate its safety and efficacy. In all cases, new information should be  
recorded and, where appropriate, made publicly available.  
Protocol Number: D035940   ILLUMENATE Pivotal  PAS Protocol  
Spectranetics Appendix C:  Trial Abbreviations and Definitions  
______________________________________________________________________________ 
  
___________________________________________________________________________ 
Confidential  Page 1 of 15 
 Trial Abbreviations  
ABI Ankle -Brachial Index  
AE Adverse Event  
ADE  Adverse Device Effect  
ASA  Acetylsalicylic Acid  
ASAP  As Soon As Possible  
AV Arteriovenous  
BBC  Bare balloon catheter  
BMI  Body Mass Index  
CBC  Complete Blood Count  
CEC  Clinical Events Committee  
CFR  Code of Federal Regulations  
CI Clinically Indicated  or Confidence Interval  
CLI Critical Limb Ischemia  
CMP  Complete Metabolic Panel  
COPD  Chronic Obstructive Pulmonary Disease  
CRF  Case Report Form  
CT Computed Tomography  
CVA  Cerebrovascular Accident  
CVD  Cardiovascular Disease  
CVI CV Ingenuity  
DSMB  Data Safety Monitoring Board  
DUS  Duplex Ultrasound  
EC Ethics Committee  
EOB  Explanation of Benefits  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
ICH International Conference on Harmonisation  
ID Identification  
IDE Investigational Device Exemption  
IFU Instructions for Use  
IRB Institutional Review Board  
ISO International Organization for Standardization  
ITT Intent -to-Treat  
IV Intravenous  
LLL Late Lumen Loss  
MAE  Major Adverse Event  
MEC  Medical Ethics Committee  
MI Myocardial Infarction  
MLD  Minimum Lumen Diameter  
MR Magnetic Resonance  
OTC  Over -the-counter  
O.U.S.  Outside the United States  
PAD  Peripheral Artery Disease  
PI Principal Investigator/Primary Investigator  
PP Per Protocol  
PSVR  Peak Systolic Velocity Ratio  
PT  Prothrombin Time  
Protocol Number: D035940   ILLUMENATE Pivotal  PAS Protocol  
Spectranetics Appendix C:  Trial Abbreviations and Definitions  
______________________________________________________________________________ 
  
___________________________________________________________________________ 
Confidential  Page 2 of 15 
 PTA  Percutaneous Transluminal Angioplasty  
QA Quant itative Angiography  
QALY  Quality -adjusted Life Year  
RVD  Reference Vessel Diameter  
SAE  Serious Adverse Event  
SADE  Serious Adverse Device Effect  
SAP Statistical Analysis Plan  
SFA Superficial Femoral Artery  
TLR  Target Lesion Revascularization  
TPG  Translesional Pressure Gradient  
TVR  Target Vessel Revascularization  
UADE  Unanticipated Adverse Device Effect  
USADE  Unanticipated Serious Adverse Device Effect  
U.S. United States  
WIQ  Walking Impairment Questionnaire  
 
Trial Definitions  
Abrupt Closure  
Vessel occlusion at the site of treatment within 24 hours after successful index procedure.  
Acute Success  
Acute success is classified according to the following definitions:  
Clinical Success  
Clinical success (per subject) is defined as technical success without the occurrence of major adverse events during the procedure . 
Lesion Success  
Lesion  success is defined as achievement of a final in -lesion residual diameter 
stenosis of ≤ 50% ( as determined by the angiographic core labor atory ), using any 
device  after wire passage through the lesion.   
Technical  Success  
Technical success is defined as achievement of a final in -lesion residual diameter 
stenosis of ≤  50% ( as determined by the angiographic core laboratory ), using the 
CVI Paclitaxel -coated Percutaneous Transluminal Angioplasty Balloon Catheter  or 
bare balloon c atheter without a device malfunction after wire passage through the 
lesion .  Pre and post -dilatation of the lesion are considered part of assigned device 
treatment.  
Adjunctive Treatment  
A procedure performed after treatment with the protocol- defined treatment  
Adverse Event s  
 
 
Protocol Number: D035940   ILLUMENATE Pivotal  PAS Protocol  
Spectranetics Appendix C:  Trial Abbreviations and Definitions  
______________________________________________________________________________ 
  
___________________________________________________________________________ 
Confidential  Page 3 of 15 
 Adverse Event (US)  An adverse event is any untoward medical occurrence  in a 
study subject which occurs or worsens, whether or not considered related to the study device, study procedures, or study requirements
.    
Adverse Event (OUS)  Any untoward medical occurrence, unintended disease or 
injury, or untoward clinical signs (including abnormal 
laboratory findings) in subjects, users or other persons, whether 
or not related to the investigational medical device.  
NOTE 1: This definition i ncludes events related to the 
investigational medical device or the comparator.  
NOTE 2: This definition includes events related to the 
procedures involved.  
NOTE 3: For users or other persons, this definition is restricted 
to events related to investigati onal medical devices.  
Serious Adverse Event 
(US)  Any untoward medical occurrence that results in death, is life -
threatening, requires inpatient hospitalization or prolongation of 
existing hospitalization, results in persistent or significant disability/incapacity,  
requires medical/surgical intervention to 
prevent life -threatening illness or injury or to prevent 
permanent impairment of a body structure or function, or is a congenital anomaly/birth defect.  Emergency room visits lasting less than 24 hours are not considered SAEs.   
Note : For purposes of reporting within this protocol, pre -
existing conditions or planned procedures for pre -existing 
conditions do not need to be reported as an adverse event or a 
SAE in the CRF unless there is an increase in severity or frequency during the course of the study. If a procedure is 
planned prior to enrollment and it is documented in the medical 
record as planned then an AE or a SAE does not need to be 
reported in the eCRF.    
Serious Adverse Event 
(OUS )  An adverse event that  
a) led to a death or  
b) led to a serious deterioration in the health of the subject that 
either resulted in:  
1) a life -threatening illness or injury, or  
2) a permanent impairment of a body structure or a body function, or  
Protocol Number: D035940   ILLUMENATE Pivotal  PAS Protocol  
Spectranetics Appendix C:  Trial Abbreviations and Definitions  
______________________________________________________________________________ 
  
___________________________________________________________________________ 
Confidential  Page 4 of 15 
 3) in-patient or prolonged hospitalization, or  
4) medical or surgical intervention to prevent life –threatening 
illness or injury or permanent impairment to a body structure or 
body function.  
c) led to fetal distress, fetal death or a congenital abnormality or 
birth defect  
 
NOTE: Planned hospitalization for a pre -existing condition, or 
a procedure required by the protocol, without serious 
deterioration in health, is not considered a se rious adverse 
event.  
Adverse Device Effect 
(ADE)  An adverse event related to the use of an investigational 
medical device.  
NOTE 1: This definition includes adverse events resulting from insufficient or inadequate instructions for use, deployment, 
impla ntation, installation, or operation, or any malfunction of 
the investigational medical device.  
NOTE 2: This definition includes any event resulting from use error or from intentional misuse of the investigational medical 
device.  
Serious Adverse Device 
Effect (SADE)  An adverse device effect that has resulted in any of the 
consequences characteristic of a serious adverse event (see 
definition above).  
Unanticipated Serious 
Adverse Device Effect 
(USADE)  Any serious device effect w hich by its nature, incidence, 
severity, or outcome has not been identified in the current version of the risk analysis report.  
NOTE: Anticipated serious adverse device effect (ASADE) is 
an effect which by its nature, incidence, severity or outcome 
has be en identified in the risk analysis report.  
 
Amputation  
The removal of a body extremity by surgery.     
A minor amputation will be defined as below the ankle; and a major amputation will be 
defined above the ankle .   
Aneurysm  
Protocol Number: D035940   ILLUMENATE Pivotal  PAS Protocol  
Spectranetics Appendix C:  Trial Abbreviations and Definitions  
______________________________________________________________________________ 
  
___________________________________________________________________________ 
Confidential  Page 5 of 15 
 A localized, pathological, blood- filled dilatation of a blood vessel caused by a 
weakening of the vessel wall.  
Angina Pectoris  
Braunwald Classification of Unstable Angina:  
New onset of severe or accelerated angina.  Patients with new onset (< 2 months in 
duration) exertional angina pectoris that is severe or frequent (> 3 episodes/day) or 
patients with chronic stable angina who develop accelerated angina (that is, angina 
distinctly more frequent, severe, longer in duration, or precipitated by distinctly less 
exertion than previously)  but who have not experienced pain at rest during the 
preceding 2 months. 
Angina at rest, subacute.  Patients with one or more episodes of angina at rest during 
the preceding month but not within the preceding 48 hours.  
Angina at rest, acute.  Patients with one or more episodes of angina at rest within 
the preceding 48 hours.  
Canadian Cardiovascular Society (CCS) Classification of Stable Angina:  
Ordinary physical activity does not cause angina; for example walking or climbing 
stairs, angina occurs with strenuous or rapid or prolonged exertion at work or 
recreation.  
Slight limitation of ordinary activity; for example, angina occurs walking or stair 
climbing after meals, in cold, in wind, under emotional stress or only during the few 
hours after awakening, walking more than two blocks on the level or climbing more 
than one flight of ordinary stairs at a normal pace and in normal conditions. 
Marked limitation of ordinary activity; for example, angina occurs walking one or 
two blocks on the level or climbing o ne flight of stairs in normal conditions and at a 
normal pace.  
Inability to carry on any physical activity without discomfort -  angina syndrome 
may be present at rest.  
Ankle Brachial Index (ABI)  
The ratio of the highest ankle systolic pressure to the highe st brachial systolic pressure.  
Anticipated Adverse Event  
Any undesirable health related experience occurring to a subject whether or not considered related to the investigational device or drug regimen prescribed as part of the protocol that is predefined in the protocol and/or I nstructions for U se that occurs  or 
worsens during a clinical study.  
Arterial Inflow  
For a lesion in the superficial femoral artery (femoro -popliteal level) inflow refers to the 
aorto -iliac level.  Good inflow implies that vessels proximal to a target treatment site 
are free of hemodynamically significant lesion s tenosis  (≥ 50%  stenosis ). 
Arterial Outflow  
For a lesion in the superficial femoral artery (femoro -popliteal level) outflow refers to 
combined levels distal to the lesion, including the following arteries: distal poplitea l, 
Protocol Number: D035940   ILLUMENATE Pivotal  PAS Protocol  
Spectranetics Appendix C:  Trial Abbreviations and Definitions  
______________________________________________________________________________ 
  
___________________________________________________________________________ 
Confidential  Page 6 of 15 
 tibioperoneal trunk, anterior tibial, posterior tibial, peroneal, dorsalis pedis, plantar and pedal.  Good outflow implies that the distal popliteal, tibioperoneal trunk and at least one of the infrapopliteal arteries (anterior tibial, posterior tibial,  peroneal) is free of 
hemodynamically significant lesion s tenosis  (≥ 50%  stenosis ) and that there is in -line 
flow into the foot. 
Arterial Dissection  
Intimal disruption of the vessel wall with or without medial or adventitial contrast staining.   
Dissection Grades  
National Heart, Lung, and Blood Institute (NHLBI) Dissection Classification System: 
(0, A, B, C, D, E, F)  
 0: No dissection.  
A:   Minor radiolucent areas in the lumen without impairment of flow or persistent 
dye staining after contrast r unoff .  
B:  Lumin al flap that is radiolucent and that runs parallel to the vessel wall with 
contrast injection but without impairment of flow or persistent dye staining 
after contrast runoff . 
C:  Contrast appears outside of the vessel lumen as an "extra- luminal cap". The 
staining appears even after contrast clears the lumen .  
D:  Spiral radiolucent luminal filling defects. Often persistent staining after 
contrast clears from the vessel.  
E:  New and persistent filling defects in the vessel lumen.  
F:  Lesions that progress to impaired flow or total occlusion.  
 
Arterial Perforation  
Identifiable by extravasation of contrast media outside the arterial adventitial space.  
Arterial Rupture 
Large transmural disruption of a vessel with gross extravasation and hemorrhage.  
Artery Spasm  
A sudden, brief tightening of a blood vessel.  
Bleeding  
Blood loss resulting from the percutaneous interventional procedure or adjunctive drug 
therapy that may require transfusion of blood products.  
 
Cerebrovascular Accident (CVA) or Stroke  
Neurological dysfunction caused by a brain disturbance or ischemia, with clinical symptoms lasting >24 hours or imaging of an acute clinically relevant brain lesion in patients with rapidly vanishing symptoms. 
Protocol Number: D035940   ILLUMENATE Pivotal  PAS Protocol  
Spectranetics Appendix C:  Trial Abbreviations and Definitions  
______________________________________________________________________________ 
  
___________________________________________________________________________ 
Confidential  Page 7 of 15 
 Compressible Artery1 
An artery witho ut significant calcification that can be evaluated by duplex ultrasound 
or an artery that results in an ABI value < 1.3.  
Death  
The termination of life.  When possible, death will be classified according to underlying 
cause.  Death within 30- days of the st udy procedure will be classified as procedure 
related unless demonstrated otherwise.   
Cardi ovascular  death:  
Any death due t o proximate cardiac cause ( e.g., myocardial infarction (M I), low -
output failure, fatal arrhythmia), unwitnessed death, or death of unknown cause.  
Device Malfunction  
A device malfunction is any case when the device does not perform in its intended 
function when used in accordance to the Instructions for Use. 
Discharge  
The time point at which the subject was released from the admitting  hospital or 
transferred to another facility.  
Embolism  
Obstruction of a blood vessel by a foreign substance (air, plaque, debris) or a blood clot. 
Enrollment  
The patient will be considered enrolled into the study upon the completion of all the following:  
• A signed patient informed consent ; 
• General and angiographic inclusion/exclusion criteria for enrollment has been 
met; 
• Successful treatment of the inflow (iliac) artery without complication, if 
applicable ; 
• Target lesion is successfully crossed by the guidewire ; 
• The pre -dilation has been completed  (with a non- study catheter that is at least 
1 mm smaller in diameter than the nearest reference vessel diameter)  without a 
flow-limiting (Grade D or greater) dissection, stent placement, or residual 
stenosis >70% ; and 
• Randomized treatment has been assigned.  
                                                            
 
11 Creager Mark, Victor Dzau, and Joseph Loscalzo, eds.  Vascular Medicine: A Companion to Braunwald’s 
Heart Disease.   Philadelphia, PA: Saunders Elsevier, 2006.  
Protocol Number: D035940   ILLUMENATE Pivotal  PAS Protocol  
Spectranetics Appendix C:  Trial Abbreviations and Definitions  
______________________________________________________________________________ 
  
___________________________________________________________________________ 
Confidential  Page 8 of 15 
 Fever   
An increase in internal body temperature to levels that are above normal (37°C, 98.6°F). 
Gastrointestinal (GI) bleeding  
Any bleeding that starts in the gastrointestinal tract, which may extend from the mouth to the anus. 
Hemorrhage  
Bleeding requiring hospitalization, repeat procedure, operation or transfusion.  
Hypertension  
Increase in systolic blood pressure above 140 mm Hg or a diastolic blood pressure above 90 mm Hg.  
Hypotension  
Fall in systolic blood pressure that requires intravenous treatment with vasopressors or inotropic agents.  
 
Index Procedure 
The procedure in which the subject has the study procedure performed or attempted. 
Infection  
Inflammation caused by bacterial or viral sources, such as, urinary tract infection, 
puncture site infection, sepsis, endocarditis, and bacteremia from IV site.   
Inflammation  
An immunologic response to infection or trauma that can result in localized redness, 
swelling, heat, pain and dysfunction of the organs involved.  
Intent -to-Treat (ITT) Population  
Subjects who successfully complete the preliminary qualification procedures and are 
subsequently randomized to receive either the investigational device (CVI  Paclitaxel -
coated PTA Catheter) or the control device ( bare balloon c atheter).  
Intraluminal thrombus  
A blood clot within a vessel.  
Invasive Assessment/Procedure 
Any assessment, intervention or therapy
 that penetrates the skin, excluding 
administration of  parenteral fluids or drugs.  
Late Lumen Loss (L LL) 
Calculated as Minimum Lumen Diameter (MLD) post -procedure – MLD at follow -up. Mean 
in-lesion Late Loss will also be measured:  (Mean In -lesion MLD, post -procedure) –  (Mean 
In-lesion MLD at follow -up).  
 
Protocol Number: D035940   ILLUMENATE Pivotal  PAS Protocol  
Spectranetics Appendix C:  Trial Abbreviations and Definitions  
______________________________________________________________________________ 
  
___________________________________________________________________________ 
Confidential  Page 9 of 15 
 Major Adverse Event (MAE)  
Events including cardiovascular death, target limb major amputation and clinically -
driven target l esion revascularization (TLR).  
Minimum Lumen Diameter (MLD) 
The average of two orthogonal views (when possible) of the narrowest poi nt within the 
area of assessment – in lesion, in stent or in segment.  MLD is visually estimated during angiography by the Invest igator  and is also measured by the Angiographic Core Lab.  
Multilevel Disease  
Presence of obstructive lesions at more than one level in the same extremity as the treatment lesion.  
Myocardial Infarction
2  
 Criteria for acute myocardial infarction: 
• Detection of a rise and/or fall of cardiac biomarker values [preferably cardiac troponin 
(cTn)] with at least one value above the 99th percentile upper reference limit (URL) 
and with at least one of the following:  
o Symptoms of ischaemia.  
o New or presumed new significant ST -segment –T wave (ST–T) changes or 
new left bundle branch block (LBBB). 
o Development of pathological Q waves in the ECG. 
o Imaging evidence of new loss of viable myocardium or new regional wall 
motion abnormality. 
o Identification of an intracoronary thrombus by angiography or autopsy.  
• Cardiac death with symptoms suggestive of myocardial ischaemia and presumed new ischaemic ECG ch anges or new LBBB, but death occurred before cardiac biomarkers 
were obtained, or before cardiac biomarker values would be increased.  
• Percutaneous coronary intervention (PCI) related MI is arbitrarily defined by 
elevation of cTn values (>5 x 99th percentil e URL) in patients with normal baseline 
values (≤99th percentile URL) or a rise of cTn values >20% if the baseline values are 
elevated and are stable or falling. In addition, either (i) symptoms suggestive of 
myocardial ischaemia or (ii) new ischaemic ECG changes or (iii) angiographic 
findings consistent with a procedural complication or (iv) imaging demonstration of 
new loss of viable myocardium or new regional wall motion abnormality are required.  
• Stent thrombosis associated with MI when detected by coronary angiography or 
autopsy in the setting of myocardial ischaemia and with a rise and/or fall of cardiac biomarker values with at least one value above the 99th percentile URL. 
• Coronary artery bypas s grafting (CABG) related MI is arbitrarily defined by elevation 
of cardiac biomarker values (>10 x 99th percentile URL) in patients with normal baseline cTn values (≤99th percentile URL). In addition, either (i) new pathological Q waves or new LBBB, or (i i) angiographic documented new graft or new native 
                                                            
 
2 Third universal definition of myocardial infarctio n. Thygesen K, et al. Eur Heart J. 2012 Oct;33(20):2551- 67 
Protocol Number: D035940   ILLUMENATE Pivotal  PAS Protocol  
Spectranetics Appendix C:  Trial Abbreviations and Definitions  
______________________________________________________________________________ 
  
___________________________________________________________________________ 
Confidential  Page 10 of 15 
 coronary artery occlusion, or (iii) imaging evidence of new loss of viable myocardium 
or new regional wall motion abnormality.  
Criteria for prior myocardial infarction  
Any one of the following criteria mee ts the diagnosis for prior MI:  
• Pathological Q waves with or without symptoms in the absence of non- ischaemic 
causes.  
• Imaging evidence of a region of loss of viable myocardium that is thinned and fails to 
contract, in the absence of a non- ischaemic cause.  
• Pathological findings of a prior MI.  
 
National Principal Investigator  
A physician -specialist, related to the study, which is responsible for the overall conduct 
of the trial at all sites  in a country.  
Occlusion  
An obstruction within an artery.  
Patency Rat e 
Patency rate defined as the absence of target lesion restenosis determined  by duplex 
ultrasound p eak s ystolic velocity r atio (PSVR) of ≤  2.5 and freedom from  clinically -
driven target lesion revascularization .   
Ultrasound evidence will be used first to determine patency.  
• Ultrasound images showing a PSVR of ≤  2.5 will be considered patent by the core 
laboratory.  In the event that the core laboratory cannot determine the PSVR , the 
core laboratory will make an assessment as to whether or not the lesion is patent, 
50-99% stenosed or occluded. 
• If ultrasound images are not  available at a follow -up or analysis time point , and if 
an angiogra m evaluation is available, the angiogram will be used to determine 
patency.  A result of ≤ 50%  residual stenosis will be co nsidered patent.  
Patent Run- Off 
A vessel starting at the popliteal artery going to the foot presenting with patent flow 
(hemodynamically insignificant stenosis of <  50% ). 
Peak Systolic Velocity Ratio  
In-lesion duplex ultrasound measurement that measures the peak velocity of blood 
(cm/second) within a lesion or stented vessel segment divided by the peak velocity of blood (cm/second) proximal to the lesion or stented vessel segment. 
Percent Diameter Stenosis  
Relative changes that occur in the percent diamet er stenosis are provided by the 
following relationship: % diameter stenosis= (1 -[MLD/Reference diameter]) x 100  
Per Protocol  
ITT subjects who had no bail -out stenting and no major protocol deviations.  The data 
for each subject will be reviewed by the blinded angiographic core laboratory.   
Protocol Number: D035940   ILLUMENATE Pivotal  PAS Protocol  
Spectranetics Appendix C:  Trial Abbreviations and Definitions  
______________________________________________________________________________ 
  
___________________________________________________________________________ 
Confidential  Page 11 of 15 
 Physician- Directed Subject Withdrawal  
Withdrawal of a subject from the study at the direc tion of the Principal Investigator.  
Reasons for physician -directed subject withdrawal include, but are not exclusive to: 
the subject is not adhering to the s tudy protocol requirements, the subject has enrolled 
in another study that conflicts with the ILLU MENATE Pivotal  outcomes of interest, 
or the physician deems it in the best interest for the safety or welfare of the subject to withdraw.  
Popliteal Artery  
Defined as the vessel located between Hunter’s canal and the trifurcation of the anterior tibial, posterior tibial and peroneal arteries.  
Pre-Procedure 
The time until the procedure begins (before arterial access is obtained).  
Protocol Deviation  
Any divergence from the Study Protocol.  
Principal Investigator (PI)  
 Physician  responsible for overall clinical management of subjects enrolled at his/her 
institution. Assumes overall responsibility and accountability for the clinical team and for data obtained from each subject participating in the study. Ensures compliance with the Study Protocol, applicable laws, and applicable regulations; ensures informed 
consents are signed, and reviews and signs eCRF indicating documents are accurate and complete.  
Reference Vessel Diameter (RVD)  
An approximation of the diameter of the vessel at  the location of the target lesion.  RVD 
is the average of vessel diameters proximal and distal to the target lesion.  It will be estimated or measured by the Investigator and also measured by the angiographic core laboratory.  
Renal Failure  
Failure of the kidneys to perform essential functions that requires dialysis.  
Restenosis  
Re-narrowing of the artery following the reduction of a previous narrowing.  It is 
defined as the presence of a PSVR ≥ 2.5 by duplex ultrasound or a hemodynamically significant restenosis (≥ 50%  stenosis ), as determined by angiography.   
Restenotic Lesion  
A lesion in a vessel segment that had undergone a prior percutaneous treatment.  
Runoff Vessel  
An artery distal to treated vessel, including the popliteal, peroneal tibials  and the 
dorsalis pedis.  
 
Protocol Number: D035940   ILLUMENATE Pivotal  PAS Protocol  
Spectranetics Appendix C:  Trial Abbreviations and Definitions  
______________________________________________________________________________ 
  
___________________________________________________________________________ 
Confidential  Page 12 of 15 
 Rutherford -Becker Classification Categories  
A classification system of clinical categories of chronic limb ischemia ranging from 0 to 6.  The categories and clinical descriptions are:  
 
Category  Clinical Description  
0 Asymptomatic, no hemodynamically significant occlusive disease  
1 Mild claudication  
2 Moderate claudication  
3 Severe claudication  
4 Ischemic rest pain  
5 Minor tissue loss, non- healing ulcer, or focal gangrene with diffuse 
pedal ischemia  
6 Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable  
 
Sepsis  
Systemic inflammatory response to infection.  
Severe Calcification   
Radiopacities  noted on both sides of the arterial wall and extending more than one cm 
of length prior to contrast injection or digital subtraction angiography.  
 
Stenosis  
An abnormal narrowing of an artery.  
Study/Research Coordinator  
Employee at study site who assists Principal Investigator with study activities as 
delegated by the Principal Investigator, including tracking subjects involved in the study, scheduling testing and follow -up visits, maintaining study records, completing 
and providing eCRFs to the s ponsor in a timely manner.  
Sub- Investigator(s)  
Physician(s) responsible for study activities in coordination with Principal Investigator and in accordance to the Study Protocol.   
Successful Pre- Dilation  
Pre-dilation (with a non- study catheter that is at least 1 mm smaller in diameter than the 
nearest reference vessel diameter) has been successfully completed without complications if all of the following apply:  
Protocol Number: D035940   ILLUMENATE Pivotal  PAS Protocol  
Spectranetics Appendix C:  Trial Abbreviations and Definitions  
______________________________________________________________________________ 
  
___________________________________________________________________________ 
Confidential  Page 13 of 15 
 • Residual d iameter stenosis ≤ 70%  
• No stent placed. 
• No flow -limiting (Grade D or greater) dissections   
Superficial Femoral Artery (SFA)  
The SFA connects to the popliteal artery  at the opening of adductor magnus  or hunter's 
canal  towards the end of the femur . 
Tandem Lesions  
Two distinct le sions with 3 cm or less of healthy vessel separating the diseased areas;  
this total area (diseased segments plus the 3 cm or less of healthy vessel) must be treatable by no more than 2 devices  and ≤18 cm in cumulative length . 
Target Lesion  
A single diseased segment, between 3  cm and 18  cm in total length, in the superficial 
femoral or popliteal arter ies that meets all the angiographic inclusion criteria and none 
of the exclusion criteria .     
Target Lesion Revascularization  (TLR)  
Re-treatment by an invasive procedure, including atherectomy, angioplasty, stenting, 
endarterectomy, bypass, or thrombolysis, performed to open or increase the lumen diameter of the target lesion. TLRs will be classified as clinically -driven or not 
clinica lly-driven  through an adjudication process.  Diameter stenosis will be 
determined per a ngiographic c ore laboratory assessment.   
Target Lesion Revascularization, Clinically- Driven : 
A revascularization of the target lesion is considered clinically -driven if the PSVR ≥ 2.5 
by duplex ultrasound or if angiography shows a percent diameter stenosis > 50% and 
there is worsening of the Rutherford Becker Clinical Category or ABI that is clearly 
referable to the target lesion. ( Worsening is defined as deterioration (an  increase) in the 
Rutherford Becker Clinical Category by more than 1 (>1)  categor y from the earliest 
post-procedural measurement or deterioration in the Ankle Brachial Index (ABI) >  0.15 
from the maximum early post -procedural level. ) 
An independent  ultraso und and/or  angiographic core laboratory will verify that the 
severity of percent diameter stenosis meets requirements for clinical ly-driven  and will 
overrule in cases where investigator reports are not in agreement . 
Target Limb  
The entire limb in which the  target lesion is located.  
Target Vessel  
The entire vessel in which the target lesion is located.  
Target Vessel Revascularization  (TVR)  
Any reintervention in the target vessel.  
Target Vessel Revascularization , Clinically Driven  
A repeat revascularization procedure (percutaneous or surgical) of a lesion in the target 
vessel, exclusive of the target lesion site.   A revascularization of the target vessel  is 
Protocol Number: D035940   ILLUMENATE Pivotal  PAS Protocol  
Spectranetics Appendix C:  Trial Abbreviations and Definitions  
______________________________________________________________________________ 
  
___________________________________________________________________________ 
Confidential  Page 14 of 15 
 considered clinically -drivent  the PSVR ≥ 2.5 by duplex ultrasound or if angiography 
shows a percent diameter stenosis > 50% and there is worsening of the Rutherford 
Becker Clinical Category or ABI that is clearly referable to the target lesion. (Worsening is defined as deterioration (an increase) in the Rutherford Becker Clinical 
Category by more than 1 (>1)  categor y from the earliest post -procedural measurement 
or deterioration in the Ankle Brachial Index (ABI) by >  0.15 from the maximum early 
post-procedural level. ) 
Thrombosis  
The formation or development of thrombus inside a blood vessel, obstructing the f low 
of blood.  
Thrombus  
A blood clot within a vessel, which obstructs the flow of blood. 
Total Occlusion  
100% stenosis within an artery.  
Transient Ischemic Attach (TIA)  
Brief episode of neurological dysfunction caused by a focal disturbance of brain or retinal ischemia, with clinical symptoms typically lasting less than 24 hour s, and 
without evidence of infarction.  
Unanticipated Adverse Device Effect (UADE)  
Any serious adverse effect on health or safety or any life- threatening problem or 
death caused by, or associated with, a device, if that effect, problem, or death was 
not previously identified in nature, severity, or degree of incidence in the investigational plan or protocol, or any other unanticipated serious problem associated with a device that relates to the rights, safety or welfare of subjects.  
Vascular  Access Complications  
Access Site Occlusion :  
Access site occlusion is defined as total obstruction of the artery usually by thrombus (but may have other causes) usually at the site of access requiring surgical repair.   
Arteriovenous Fistula  
A communication between an artery and a vein in which the a rterial blood flows 
directly into a neighboring vein.  
Peripheral Embolization  
Peripheral embolization is defined as a loss of distal pulse, pain and/or discoloration (especially the toes).  This can include cholesterol emboli.  The site should i ndicate 
whether a peripheral embolization occurred distal to the arterial access site during the procedure or after lab visit but before any subsequent lab visits, requiring therapy.  
Pseudoaneurysm  
Perforation of the vessel with arterial blood flow outsi de of the vessel.  
Protocol Number: D035940   ILLUMENATE Pivotal  PAS Protocol  
Spectranetics Appendix C:  Trial Abbreviations and Definitions  
______________________________________________________________________________ 
  
___________________________________________________________________________ 
Confidential  Page 15 of 15 
 Hematoma  
Localized mass of extravasated blood ≥ 5 cm that prolongs hospitalization. 
Retroperitoneal Bleed  
An accumulation of blood in the retroperitoneal space . 
Peripheral  Ischemia 
A restriction in arterial blood flow by stenosis, restenosis or occlusion that, if 
prolonged, can lead to tissue damage.  
Walking Impairment Questionnaire (WIQ)  
A disease- specific instrument utilized to characterize walking ability through a 
questionnaire.  It is a measure of patient -perceived walking performance for patients 
with PAD and/or intermittent claudication.   
 
 
 
Confidential    Page 1 of 1 
 ILLUMENATE Pivotal  PAS 
  
APPENDIX D :  Rutherford -Becker Classification  Guidelines  
 
Rutherford- Becker Classification1 is a classification system of Peripheral Arterial Disease.  
Determination of Rutherford- Becker Classification is required at the following time points:  
 
• 24 and 36 month follow -up visits  
• Unscheduled visits and re -interventions  
 The Rutherford- Becker Classification is a global assessment based on the clinical description.  
 
Category Clinical Description  
0 Asymptomatic --no hemodynamically significant occlusive disease  
1 Mild claudication  
2 Moderate claudication  
3 Severe claudication  
4* Ischemic rest pain  
5* Minor tissue loss -nonhealing ulcer, focal gangrene with diffuse pedal 
ischemia  
6* Major tissue loss -extending above transmetatarsal level, functional foot 
no longer salvageable  
*Categories 4, 5, and 6 are also described as critical limb ischemia.  
 
         
  
 
______ 
1 Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, Jones DN. Recommended 
standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997 Sep;  
26(3):517 -38. 
 

Confidential    Page 1 of 3 ILLUMENATE Pivotal  PAS
  
 
 
APPENDIX E:  Ankle Brachial Index (ABI) Guidelines  
Determination of Ankle Brachial Index (ABI) is required for each subject  (study treatment limb only)  at the 
following time points:  
• 24 and 36 month follow -up visits  
• Unscheduled  and Re -intervention visits 
 
The ABI assessment is required to be attempted at the required time points given above.  If the ABI is not 
attempted at a required time point, it will b e a protocol deviation  (except at unscheduled or re -intervention 
visits) . If the ABI result cannot be calculated due to a non-compressible artery, then it will not be a protocol 
deviation.  
Performing the ABI is a fast and effective non -invasive tool for screening for Peripheral Arterial Disease.  
Interpreting the ABI results are described in the table below.  
ABI Results  Indication  
0.96 or Above  Generally normal  
0.81 – 0.95 Mild disease  
0.51-0.80 Moderate disease  
0.31-0.50 Moderate to severe disease  
0.30 or below  Severe disease  
 
Preparing the Patient:  
1. The patient should have refrained from smoking for at least 1 hour prior to the testing.  
2. It is recommended that the same size cuff is used for both brachial and ankle pressures for an 
assessment and for each study visit.  
3. Have the patient remove shoes, socks/stockings and slacks if they cannot be easily rolled up to the 
knee. Shirts or blouses should be able to be easily rolled up to allo w adequate placement of a blood 
pressure cuff on the arm. If clothing inhibits placement of the cuff or constricts the extremity, it 
should be removed.  
4. Make sure the patient is comfortable and warm. Cover patient with a sheet or blanket if desired.  
5. The pat ient should be allowed to rest quietly for at least 5 minutes prior to beginning the test.  
6. Bilateral ABI is useful at baseline if the target limb has not yet been confirmed.  At follow-up visits, only the target limb ABI is required.  The database only req uires entry of the target limb ABI 
for all visits.  
Automatic vs. Manual Assessment  
ABI may be assessed using an automatic ABI machine or assessed manually.   
Automatic ABI Assessment  
For automatic ABI assessment, please follow the equipment instructions to obtain the ABI readings.   

Confidential    Page 2 of 3 Manual ABI Assessment  
For manual ABI assessments please refer to the guidelines below:  
Equipment:  
• Vascular Doppler with 5 or 8 MHz probe  
• Ultrasound gel  
• Blood pressure cuff (same size cuff for each subject for all visits is recommended)  
• Sphygmomanometer  
• Pen, paper, and calculator  
 
Performing the Exam:  
1. For first assessment for the subject, select the appropriate size cuff. An inappropriately sized blood 
pressure cuff will affect your results. It is recommended that the cuff bladder be 20% wider than the 
extremity diameter.  
a. Use the same size cuff for both arm and ankle measurements.  
b. It is recommended that you use the same size cuff consistently for all visits for the subject.  
2. Arm Pressure:  
Obtain brachial systolic pressure per your site’s SOC.  If using a Doppler probe, follow these 
guidelines:  
a. Place the appropriate sized cuff midway on the patient’s upper arm. Approximately two finger 
widths should exist between the crease in the antecubital space and the bottom of the cuff. The 
cuff should not be placed over the elbow area or cover the antecubital space.  
b. Attach the sphygmomanometer.  
c. Squeeze out approximately a dime sized amount of ultrasound gel and spread it over the 
antecubital space locating the brachial artery using the tip of the Doppler probe. Slowly move the probe across the brachial area until you hear the “whooshing” sound. Once you locate the brachial artery, adjust the volume on the probe so the signal can be easily heard. This position 
should be maintained throughout the rest of the procedure. To steady your hand (so you don’t 
lose placement) you may gently rest your hand on the patients arm.  
d. Begin inflating the blood pressure cuff. You will continue to hear blood moving through the artery. As you continue to inflate the cuff, the pressure of the cuff will stop the flow of blood through the artery.  Stop inflating the cuff approximately 10-20 mmHg past the point where 
you no longer heard the sound.  
e. Slowly deflate the cuff by 1 -2 mm increments.  At the point where the sound returns, make note 
of the location of the gauge needle. Record this as the systolic pressure. Once you have 
accomplished this you may rapidly deflate the cuff the down to 0 mmHg . 
f. Repeat this procedure on the opposite arm.  
g. If you miss hearing the sound while deflating the cuff -allow 5 minutes before reattempting the 
procedure.  Repeat the steps above.  
h. Record the data collected.  
3. Ankle pressure:  
a. Two locations are available for obtai ning ankle pressure; the posterior tibial (PT) artery is 
preferred although you can use the dorsalis pedis (DP) artery.  Attempt to locate the PT (located 
just behind the medial ankle bone) and use this as your measurement. The DP (top of foot) may be used  for calculating the ABI only if PT is non-compressible.  Be advised that pressing too 
hard on the DP will obliterate the sound. Gentle pressure is to be used.  
b. Use the same cuff size as was used on the patient’s arm. Wrap the cuff snugly around the 
patient ’s ankle, just above the foot. Have patient rotate the foot outward 
c. Attach the sphygmomanometer.  
Confidential    Page 3 of 3 d. Squeeze out approximately a dime sized amount of ultrasound gel out over the PT (or DP if 
needed) and place the probe. Spread the gel around and using the probe listen for the 
whooshing sound indicating blood flow. When you locate the sound, adjust the volume of the 
probe and maintain your position for the remainder of the procedure. Again, you may rest your 
hand gently on the patient’s foot to steady it.  
e. Begin inflating the blood pressure cuff. You will continue to hear blood moving through the 
artery. As you continue to inflate the cuff, the pressure of the cuff will stop the flow of blood 
through the artery.  Stop inflating the cuff approximately 10-20 mmHg pa st the point where 
you no longer heard the sound.  
f. Slowly deflate the cuff by 1 -2 mm at a time. When the sound reappears record this as your 
systolic pressure. Once you have accomplished this you may rapidly deflate the cuff down to 0 
mmHg.  
g. Repeat this procedure on the other ankle if obtaining bilateral ABIs.  
h. If you miss hearing the sound while deflating the cuff -allow 5 minutes before reattempting the 
procedure. Repeat the steps above.  
i. Record the data collected.  
 
Calculating the ABI  
1. When both brachial press ures and at least one ankle pressure has been obtained, select the highest 
brachial value.  
2. In patients with diabetes and heavily calcified vessels, the arteries are frequently not compressible.  If 
you miss hearing the whooshing sound after repeated attem pts (two or more times at one location) 
either before inflating the cuff or while deflating the cuff, the vessel is not compressible.  Non -
compressible arteries may result in artificially elevated pressure which in turn underestimates disease 
severity.   T he goal of obtaining an ABI is to measure an artery without significant calcification and 
results in an ABI value < 1.3.  
3. Divide the ankle pressure by the highest brachial pressure. The result is the ABI.  
 
Confidential    Page 1 of 1 
  ILLUMENATE Pivotal  PAS 
  
APPENDIX F :  Walking Impairment Questionnaire  (WIQ) 
Guidelines  
 
Completion of the Walking Impairment Questionnaire is required for eligible subjects at the following time 
points:  
• 24 and 36 month follow -up visits  
• Unscheduled visits and re-interventions  
 
The Walking Impairment Questionnai re is a functional assessment focusing on the difficulty a subject 
experiences when walking.  The questionnai re can be useful in determining the effectiveness of the study 
treatment by evaluating the subject’s severity of symptoms, and walking abilit y (distance and speed). 
 
The WIQ is an interviewer-administered questionnai re.  The interviewer should administer the WIQ by asking 
the subject the questions as they are presented on the worksheet, and recording all responses in the space 
provided. In order for the assessment to be evaluable,  the subject needs to provide an answer for every 
question for walking distance and walking speed.  A response must be provided for each question. Only in the 
event an entire group of questions under a numerical category are left blank can this be left blank in the EDC.  
If a subject does not have experience with stair climbing,  do not mark a response and leave the field blank.   
 
The WIQ results from each visit should be recorded on the CRFs  for the 24 and 36 month follow -up visits .  
This form should also be completed if the subject returns for an unschedule d visit or a re -intervention .  After 
each assessment, enter the data into the EDC. 
 

Confidential    Page 1 of 1 
 ILLUMENATE Pivotal  PAS 
  
APPENDIX G :  6 Minute Walking Test Instructions  
 
The 6 Minute Walking Test  is required at the following time points: 
 
• 24 and 36 month follow -up visits  
 
 
Instructions  
 
Set Up:   
• Measure out 30 meters in geographies using the metric system, or 100 feet for geographies using the 
English system of measure.  Preferably, in a long hallway (without corners or turns) or other flat, hard 
surface with interval markings every 3 meters, or 10 feet. Use of a treadmill, oval or circular tr ack for 
this test is not recommended.  
• Mark the boundaries of the course with cones or brightly colored tape.   
• If possible, use a quiet, straight hallway for the test.  
• Have one or more chairs available along the course for the subject to rest in if needed during the test.  
 
Administration: 
• Ask the subject to wear comfortable footwear and clothing on the day of the test.  
• Do not walk with or behind the subject.  If the subject has an oxygen tank do not push the tank, instead 
have the subject walk with it as he/she would at home.  
• Do not conduct the test with multiple people at one time.  
• Instruct the subject to walk as far as they can in 6 minutes at their usual pace or at a comfortable pace 
and to use any walking aids normally used (e.g. a cane).  
• Count laps w ith a lap counter.  
• Time the test with a stopwatch.  
• Encouragement can affect the outcome of the test.  No encouragement should be given to subjects while 
conducting the test.  
 
 
 
 
 
 
 
 
 
 

ILLUMENATE Pivotal  PAS  
 
APPENDIX H:  EQ-5D Instructions 
Confidential    Page 1 of 1                                   
 
  
The EQ -5D Questionnaire is required for each subject at the following time points:  
 
 24 and 36 month follow -up visits  
 Unscheduled visits and re-interventions  
 
 The EQ -5D is a standardized measure of health status developed by the EuroQuol  Group in order to provide a simple, 
generic measure of health for clinical and economic appraisal.  Applicable to a wide range of health conditions and 
treatments, it provides a simple descriptive profile and a single index value for health status that can be used in the 
clinical and economic evaluation of health care as well as in population health surveys.  
 
EQ-5D is designed for self -completion by subjects and is intended to reflect the health status at the time of 
completion .  Instructions for completio n are included within the questionnaire.   It should be completed prior to any 
other assessments in order to capture the subject’s self -assessment prior to discussions with the site personnel.  
 
EQ-5D is two pages in length with two sections, the EQ-5D descr iptive system and the EQ visual analogue scale 
(VAS) .  The EQ -5D descriptive system comprises the following five dimensions: mobility, self -care, usual activities, 
pain/discomfort and anxiety/depression.  Each dimension has three levels: no problems, some problems, severe 
problems.  The subject is asked to indicate his/her health state by ticking or placing a cross in the box against the most appropriate statement in each of the five dimensions.  The decision results in a one digit number expressing the level 
selected for that dimension.  The digits for five dimensions can be combined in a five digit number describing the 
respondent’s health state.   
 
The EQ VAS records the respondent’s self -rated health on a vertical, visual analogue scale where the endpoints are 
labeled ‘Best imaginable health state’ and ‘Worst imaginable health state.’  
 
Reference:  EQ-5D User’s Guide, EuroQOL Group, 2009 (www.euroqol.org).  
Protocol Number : D035940   ILLUMENATE Pivotal  PAS Protocol  
Spectranetics Appendix I :  Investigators Responsibilities  
_________________________________________________________________ 
 
Confidential    Page 1 of 1 
 Investigators Responsibilities  
1. Have and maintain the resources necessary to conduct the clinical investigation 
properly.  
2. Ensure that conducting the clinical investigation is not nor will not cause a conflict of interest.  
3. Obtain from the sponsor information which the clinical investigator judges essential about the device and be familiar with this information. 
4. Understanding of the protocol  prior to signing it.  
5. Compliance with the protocol  and any amendments.  
6. Support the monitor in their activities to verify compliance with the protocol , to 
perform source data verification, and to correct case report forms where inconsistencies or missing data is identified.  
7. Discuss with the sponsor and monitor any question of modification of the clinical investigation plan and obtain written approval of the sponsor.  
8. Ensure the clinical investigation plan is followed by all persons responsible f or the 
conduct of the clinical investigation at the institution.  Any deviation must be documented and reported to the sponsor.  
9. Make the necessary arrangements to ensure the proper conduct and completion of the clinical investigation.  
10. Make the necessary ar rangements for emergency treatment, as needed, to protect the 
health and welfare of the subject.  
11. Ensure that appropriate Institutional Review Board (IRB) or E thics C ommittee  (EC)  
approval has been received prior to the start of the clinical investigation a t the center.  
12. Provide the results from the IRB/EC to the sponsor. 
13. Inform the IRB/EC and request opinion and/or approval for any significant change in 
the clinical investigation plan that has been approved by the sponsor.  
14. Inform the IRB/EC about any serious  adverse event  and/or unanticipated adverse device 
effect, as applicable.  
15. Inform the sponsor about all adverse events , serious adverse events, and unanticipated 
adverse device effects in a timely manner.  
16. Attempt to ensure an adequate recruitment of subjects.  
17. Ensure that the subject has adequate information to give informed consent. 
18. Ensure that informed consent is obtained and documented. 
19. Ensure that clinical records are clearly marked to indicate the subject is enrolled in a particular clinical inves tigation.  If appropriate, subjects enrolled in the clinical 
investigation must be provided with some means of showing their participation in the investigation, together with identification and compliance information for concurrent treatment measures.  Con tact addresses/telephone numbers must be provided.  If 
appropriate, the subject’s personal physician should, with the subject’s agreement, be 
informed.  
20. Provide subjects with well -defined  procedures for any emergency situation and 
safeguard the subject’s in terest.  Under these circumstances, deviations from the clinical 
investigation plan will not require the prior approval of the sponsor or the IRB/EC.  
Such deviations must not be considered as a breach of agreement but shall be documented and reported to t he sponsor.  